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       Epidermal growth factor receptor (EGFR) is a cell membrane tyrosine kinase 
receptor and plays a pivotal role in regulating cell growth, differentiation, cell cycle, 
and tumorigenesis.  Deregulation of EGFR causes many diseases including cancers.  
Intensive investigation of EGFR alteration in human cancers has led to profound 
progress in developing drugs to target EGFR-mediated cancers.  While exploring 
possible synergistic enhancement of therapeutic efficacy by combining EGFR tyrosine 
kinase inhibitors (TKI) with other anti-cancer agents, we observed that suberoylanilide 
hydroxamic acid (SAHA, a deacetylase inhibitor) enhanced TKI-induced cancer cell 
death, which further led us to question whether SAHA-mediated sensitization to TKI 
was associated with EGFR acetylation.  What we know so far is that SAHA can inhibit 
class I and II histone deacetylases (HDACs), which could possibly preserve acetylation 
of underlying HDAC-targeted proteins including both histone and non-histone proteins.  
In addition, it has been reported that an HDAC inhibitor, TSA, enhanced EGFR 
phosphorylation in ovarian cancer cells.  EGFR acetylation has also been reported to 
play a role in the regulation of EGFR endocytosis recently.  These observations indicate 
that there might be an intrinsic correlation between acetylation and phosphorylation of 
EGFR.  In other words, the interplay between EGFR acetylation and phosphorylation 
may contribute to HDAC inhibitors (HDACi)-augmented EGFR phosphorylation.  
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       In this investigation, we showed that CBP acetyltransferase acetylated EGFR in 
vivo.   In response to EGF stimulation, CBP rapidly translocated from the nucleus to the 
cytoplasm.  We also demonstrated protein-protein interaction between CBP and EGFR 
as well as the enhancement of EGFR acetylation by CBP.  Moreover, EGFR acetylation 
enhanced EGFR tyrosine phosphorylation and augmented its association with Src 
kinase. Acetylation-deficient EGFR mutant (EGFR-K3R) significantly reduced the 
function and activity of EGFR.  Furthermore, ectopic expression of EGFR-K3R mutant 
abrogated its ability to respond to EGF-induced cell proliferation, DNA synthesis, and 
anchorage-independent growth using cell-based assays and tumor growth in nude mice.  
In addition, we demonstrated that EGFR expression was associated with SAHA 
resistance in the treatment of cancer cells that overexpress EGFR.  The knockdown of 
EGFR in MDA-MB-468 breast cancer cells could sensitize the cells to respond to 
SAHA.  The overexpression of EGFR in SAHA-sensitive MDA-MB-453 breast cancer 
cells rendered the cells resistant to SAHA.  Together, these findings suggest that EGFR 
plays an important role in SAHA resistance in breast carcinoma cells that we tested.  
The combination therapy of HDACi with TKI has been proposed for treating cancers 
with aberrant expression of EGFR. The evidence from pre-clinical or clinical trials 
demonstrated significant enhancement of therapeutic efficacy by using such a 
combination therapy.  Our in vivo study also demonstrated that the combination of 
SAHA and TKI for the treatment of breast cancer significantly reduced tumor burden 
compared with either SAHA or TKI alone.  The significance of our study elucidated 
another possible underlying molecular mechanism by which HDACi mediated 
sensitization to TKI.  Our results unveiled a critical role of EGFR acetylation that 
regulates EGFR tyrosine phosphorylation and may further provide an experiment-based 
rationale for combinatorial targeted therapy.   
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1. 1 The biology of EGFR 
       Epidermal growth factor receptor is a membrane tyrosine kinase receptor that 
belongs to the EGF tyrosine kinase receptor family consisting of EGFR (ErbB1), Her2 
(ErbB2), ErbB3, and ErbB4 (1, 2).  The molecular weight of EGFR is about 165 kDa. 
EGFR monomer is composed of four domains (3), namely extracellular, 
transmembrane, intracellular (including kinase domain), and cytoplasmic tail (4, 5) 
(Figure1).  Human EGFR gene is located on chromosome 7 within p13 and q22 region 
(6, 7).  According to the literature, EGF or other grow factors can cause that EGFR 
changes its extracellular domain structure and then trigger dimerization of intracellular 
domain (8-15).  In response to growth factors, EGFR forms either homodimer or 
heterodimer with other family members, therefore subsequently changes its protein 
structure and protein interaction with numerous intracellular proteins (16-19) (Figure2).  
Meanwhile, EGFR is subject to autophosphorylation or transphosphorylation that plays 
important roles in regulating several signaling pathways, namely MAPK, Akt, and Stat 
pathways (20-22).  There are several critical tyrosine phosphorylation sites in the 
intracellular domain of EGFR, namely Y845, 992, 1045, 1068, 1086, and 1173.  These 
differential phosphorylation sites correspond with different signal pathways and 
functions (21).  Generally speaking, Y845 is associated with Stat signaling pathway.  
Y992, 1068, 1086, and 1173 are generally linked to MAPK and Akt signaling pathways 
(21), while Y1045 phosphorylation is associated with the interaction of Cbl that 
regulates EGFR ubiquitination and degradation (23).  However, it is still unclear what 
determinates these phosphorylation sites and how an individual site is regulated.  
Environmental stimuli like ligands, IR, and UV have been reported to induce receptor 
tyrosine phosphorylation and/or ubiquitination (22, 24, 25).  According to the literature,  
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Figure 1  Domain structure of EGFR  
EGFR consists of extracellular domain (ECD), transmembrane region (TM), 
intracellular domain including kinase domain and cytoplasmic tail (CT).  N: amino 
terminus, C: carboxyl terminus.   
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EGF induces EGFR phosphorylation including Src-mediated transphosphorylation and 
autophosphorylation.  Phosphorylation of EGFR at Y1045 provides a docking site for 
Cbl, an E3 ubiquitin ligase, for binding to EGFR and inducing EGFR ubiquitination. 
This modification controls EGFR recycling, translocation, and degradation.  Three 
types of EGFR ubiquitination including mono-, multi-, and poly-ubiquitination are also 
involved in this process, which play different roles in EGFR function (26-28).  
Although IR and UV are also able to induce EGFR phosphorylation and/or 
ubiquitination (22, 25, 29), however, these stimuli may not affect EGFR modification 
patterns in the same way.  Among four family members, EGFR is one of the most 
critical and well-studied cell surface tyrosine kinase receptor that plays a pivotal role in 
controlling cell growth, differentiation, motility, and cell cycle (30).  As a key member, 
EGFR is essential for cell growth or tumorigenesis (31-35).   
       The regulation of EGFR is through several mechanisms that include protein 
endocytosis (36-39), ubiquitin-proteasome dependent degradation (23, 40, 41), 
lysosomal degradation, and protein cytoplasmic and nuclear shuttling (42, 43).  
Provided that EGFR signaling is too strong, to maintain cellular balance, there are 
several processes that can be utilized by the affected cells. First of all, in order to 
alleviate cellular stimulation and maintain cellular balance, protein endocytosis 
generally down-regulates EGFR signaling by reducing surface EGFR number in 
response to cellular negative feedback signals (44, 45). Second, EGFR can be 
phosphorylated at Y1045 site that recruits Cbl E3 ligase and subsequently ubiquitinates 
EGFR (46).  The ubiquitinated EGFR is then degradated by proteasome (47).  Because 
of degradation function of Cbl-catalyzed protein ubiquitination, Cbl has been 
considered as a negative regulator in EGFR-regulated signal pathways (48-50).  
Ubiquitination of protein has been considered as a marker for protein degradation.  
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However, recent study demonstrated that not all EGFR ubiquitination was subject to 
degradation.  In general, poly-ubiquitination leads to protein degradation, mono- or 
multi-ubiquitination is conferred to play a regulatory role with respect to EGFR 
function (26-28).   Besides protein ubiquitination, there are several EGFR modifications 
similar to ubiquitination such as neddylation and sumoylation. Neddylation of EGFR is 
catalyzed by Cbl as well (51). The function of EGFR neddylation is very similar to 
ubiquitination.  In summary, these Cbl-mediated EGFR modifications play an important 
role in negatively regulating EGFR signals in cell behavior and growth.    
       Another important negative regulation of EGFR phosphorylation is protein 
dephosphorylation by phosphatases.  There are several identified phosphatases such as 
PTP1B (52-55), SHP-1 (56-58), and SHP-2 (59-62), which play very important roles in 
balancing EGFR phosphorylation and activation. These phosphatases act as negative 
regulators by removing phosphoryl group from relative tyrosine residues and mitigate 
EGFR activation and signal transduction. DEP-1 was recently reported as EGFR-
regulating phosphatase by an unbiased screen approach (63).  There are several 
additional phosphatases that have been reported to interact with EGFR (64, 65). 
Deregulation of phosphatases could cause various diseases including cancers (65).   
       EGFR shuttling is also regarded as an EGFR regulating pathway.  As far as EGFR 
protein shuttling or trafficking and localization, it may be involved in many different 
functions depending on its differential modifications and interacting proteins as well as 
cellular locations (23, 66, 67).  EGFR has been reported to translocate into the 
mitochondria that regulates cell growth and proliferation (68, 69). An increasing 
number of evidence has demonstrated that EGFR trafficking and cellular locations are 
associated with abnormal cell growth as well as resistance to conventional therapeutic 
regimens for EGFR-associated diseases, most frequently in cancers such as lung cancer 
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and glioblastoma multiforme (70, 71).  For example, EGFR nuclear localization has 
been shown to associate with cancer resistance to antitumor agents like chemo-therapy 
and radiation therapy (70, 72-74).  In addition, our laboratory has demonstrated that 
EGFR can shuttle from cell surface into the nucleus, which could participate in direct 
gene regulation (75).    
       A considerable body of evidence has demonstrated that the aberrant expression of 
EGFR results in many health problems and is a culprit in many life-threatening diseases 
such as cancers of the brain, head and neck, lung, colon, and skin (5, 76-83).  A number 
of reports demonstrated that EGFR overexpression was highly correlated with non-
small cell lung cancers (NSCLC) and pancreatic cancer in clinical studies (82, 84-86).  
Accordingly, 93% tissue samples from NSCLC patients and 69% pancreatic cancer 
tissue samples expressed high levels of EGFR (84, 86). Moreover, EGFR has been 
considered as a negative prognostic indicator in cancer treatment (87, 88). Clinical 
studies demonstrated that EGFR overexpression was significantly correlated with high 
tumor grade (89-91).  A plausible of evidence showed that EGFR overexpression was 
correlated with shorter overall survival in the early stages of NSCLC and pancreatic 
cancer (89, 92, 93).  Not only cancers, EGFR is also closely correlated with various 
biological abnormalities.  Genetic study demonstrated that knockout of EGFR resulted 
in embryonic lethality (83, 94-96).  EGFR is also essential for skin development and 
associated with epithelial tumor formation (79). In addition, EGFR is associated with 
controlling circadian clock (97, 98),  eye development (99), renal development and 
disease (100), and liver regeneration (101).  The defect of EGFR expression could cause 
neurodegeneration (102-105).  Most recently, EGFR was reported to be inversely 
correlated with G-CSF-induced mobilization of hematopoietic stem and progenitor cells 
(HSPCs) from bone marrow into peripheral blood (106).  Tyrosine kinase inhibitor, 
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erlotinib, could significantly augment G-CSF-induced mobilization of HSPCs.  
Traditionally, hematopoietic cells are considered as EGFR null and used for model cells 
to study EGFR function.  The significance of this finding discloses insights into EGFR-
regulated hematopoietic stem cells and indicates that the function of EGFR may be far 
beyond what we have known currently.       
       As far as clinical relevance of EGFR in cancer treatment, mutations of EGFR link 
with cancer sensitivity and resistance to conventional therapeutical regimens and 
tyrosine kinase inhibitors (1, 4, 21, 107-113).  Since EGFR is such an important 
membrane molecule and involved in critical cellular regulations as well as many 
disease, a great deal of effort has been put into this area to understand underlying 
mechanisms that are associated with physiological and/or pathological cellular 
regulation. Therapeutic reagents that target EGFR are under development and 
promising for treating various diseases (114). For example, gefitinib exhibited 
significant efficacy in the treatment of lung cancer with several specific somatic 
mutations on EGFR (1, 4, 107). Humanized monoclonal antibodies have been 
developed to target EGFR-expressing cancers such as lung cancer, colon cancer, and 
breast cancer (115, 116).  The further study that deciphers EGFR regulation, mutation, 
protein modification, trafficking, and localization will ultimately benefit for the 
treatment of EGFR-associated diseases.  Moreover, based on our knowledge about this 
molecule, we can even develop personalized medicine and therapeutic regimens that 
effectively treat various diseases based on genetic background of patients (117-121).     
 
1. 2 The biology of protein posttranslational modifications (PTM) 
       There are more than 200 different types of protein PTM (122).  Generally accepted 
concept is that protein PTM provide surface recognition sites for protein interaction.   
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Figure 2  EGFR forms homodimer or heterodimer with Her2, ErbB3, and ErbB4 
Two distinct signal pathways may be involved in the following functions upon the 
dimerization of EGFR with its partner, namely, canonical cytoplasmic pathways and 
nuclear translocation pathway. 
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Therefore, the protein code concept has been proposed to elucidate the function of 
protein PTM (123). Recently, a growing number of published papers demonstrated that 
a wide range of proteins had gone through extensive PTM and linked with different 
functions (124-129).  EGFR is one of those identified proteins that is subject to PTM in 
order to perform its biological functions, such as glycosylation, phosphorylation, 
ubiquitination, neddylation, and sumoylation (129-133).  Depending on the type and 
pattern of EGFR modifications, modified EGFR plays different roles in regulating 
proliferation, differentiation, cell cycle, and migration. In response to environmental 
challenges and stimulation, EGFR as a surface molecule senses and responds to such 
signals as well as triggers signal cascades all the way down to the nucleus in which 
dictates biological processes in the affected cells.  In addition, modified EGFR itself can 
also translocate into the nucleus to perform regulatory function in the cells.  Since 
phosphorylation and ubiquitination of EGFR are the most important PTM and have 
been intensively studied, in this dissertation, I will mainly review recent progress of 
phosphorylation and ubiquitination of EGFR in the combination of newly identified 
EGFR PTM.   
       With limited genome for encoding genes and translating proteins (134-136), an 
organism can still generate numerous functional molecules to respond to environmental 
challenges and/or hazards through a series of biological processes (122, 137-141). For 
example, alternative splicing, genetic, epigenetic, and protein modifications (126, 127, 
142). Protein PTM such as phosphorylation, ubiquitination, sumoylation, methylation, 
and acetylation largely diversify protein function.  Depending on modification type, 
pattern and subcellular location, modified proteins may act as potent activators or 
suppressors against their unmodified counterparts. Protein PTM are involved in a 
variety of protein families including histone and non-histone proteins (124, 126, 127, 
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143, 144).  PTM expand array of biological molecules that make up for insufficient 
genetic expression and make an organism possible to respond to complicated biological 
processes with sufficient functional molecules.  Protein PTM play profound biological 
roles in regulating cell growth and proliferation and maintaining homeostasis in an 
organism.  
       Up to now, protein phosphorylation is a well-studied area and mature field. 
Phosphorylation of protein includes tyrosine, serine, and threonine residues.  Protein 
phosphorylation is involved in almost every aspect of biological processes (65, 145-
151),  For example, cell surface membrane protein activation, signal transduction, cell 
cycle, protein stability and shuttling, DNA repair, transcription, translation, and cellular 
regulation. To some extent, protein phosphorylation dictates entire cellular processes.  
Deregulation of protein phosphorylation is associated with many diseases including 
cancers and genetic diseases.  It is also well understood that EGFR phosphorylation 
plays a key role in regulating its function and controls cell cycle and growth (149).  
Detailed mapping of phosphorylation sites in EGFR has been published as well (21, 
152).  Accordingly, tyrosine phosphorylation of EGFR is critical in controlling its 
function.  In addition, EGFR-regulated downstream signal pathways are also controlled 
by phosphorylation cascades.     
       Protein ubiquitination became a hot spot recently.  For a long period of time, 
scientists believed that proteins were not subject to degradation.  However, since 
groundbreaking work on protein ubiquitination from Drs. Ciechanover and Hershko 
was accepted (153, 154), protein degradation has been widely accepted and extensively 
studied (155).  Scientist and researchers gradually gain more and more insights about 
protein stability and degradation in biological processes.  While a number of reports 
showed that protein ubiquitination was a marker for protein degradation, increasing 
 11
evidence demonstrated that not all protein ubiquitination is subject to degradation.  
Depending on the type of protein ubiquitination such as mono-, multi-, or poly 
ubiquitination, the modified proteins may have different fates but not all go through 
degradation (156).  Currently, it has been proved that EGFR is also subject to these 
differential ubiquitination modifications (27).  These suggested that protein PTM are 
indeed complicated biological processes.    
        With respect to protein acetylation and methylation, however, our previous 
knowledge only limits in a range of histone protein.  Although, histone acetylation was 
reported in the early 1960s, little is known about its function and regulation in cellular 
process until the middle1990s (144, 157, 158).  Currently, Discovery of acetylation of 
non-histone proteins has been accelerated and spans through almost all cellular 
compartments from membrane, cytoplasm, mitochondria, to the nucleus. These proteins 
include transcription factors E2F1, Stat3, -catinin, NF-B, MyoD, p53, cytoplasmic 
proteins Ku70, tubulin, IKK, MEK2, membrane proteins, and mitochondrial 
components (124, 126, 144, 159-163).  Currently, the most intensively studied protein 
acetylation is N-acetylation including -acetylation and -acetylation (144).  Although, 
protein O-acetylation has recently been reported to play a role in regulating MEK2 and 
IKK function (144, 163, 164), in our study, since the most important signal-regulating 
domains of EGFR reside in the cytoplasmic domain, therefore we are focusing on lysine 
N-acetylation that is anticipated to play a major role in EGFR function.  We expect that 
N-acetylation of EGFR, if exists, may not be critical for EGFR function.   
       Protein lysine N-acetylation is a reversible enzyme-mediated process that is 
involved in two groups of enzymes, namely histone acetylases (HATs) and histone 
deacetylases (HDACs).  HATs consist of MYST, CBP/p300, and GCN5-related N-
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acetylase families (165).  MYST family includes Esa1, MOF, MOZ, Sas2, Tip60, and 
Ybf2.  GCN5-related acetylase family includes Elp3, GCN5, and PCAF.  CBP/p300 
family is so called cAMP response element binding protein family and includes CBP 
and p300.  So far as deacetylases, there are four classes of enzymes that are comprised 
of at least 18 histone deacetylases (HDACs) in human (166, 167).  The class I is 
comprised of HDAC1, 2, 3, and 8.  The class II includes class IIa consisting of HDAC4, 
5, 7, and 9 (a and b isoforms) and class II b consisting of HDAC6 and HDAC10.  
HDAC11 belongs to the class IV.  The class III includes SIRT1, 2, 3, 4, 5, 6, and 7.  In 
the nucleus, neither HATs nor HDACs directly bind to DNA.  The function of two 
groups of enzymes usually forms complexes with other nucleus proteins and regulates 
gene expression in an opposite fashion (166, 168).  Recently, more and more non-
nuclear proteins have been discovered as substrates of these enzymes.  Moreover, more 
evidence demonstrated that the function of these enzymes is beyond the modulators of 
gene expression.  The aberrant expression of either HATs or HDACs is associated with 
many human cancers (165).    Therefore, the understanding of these groups of protein 
enzymes may help us to effectively treat a various types of human disease including 
cancers.   
       Protein acetylation plays an important role in the regulation of cellular function.  
Anti-HDAC therapy is emerging as an important field for anticancer therapy (166, 169-
173).  A growing number of anti-deacetylation therapies are undergoing clinical trials 
for the treatment of cancers.  Despite these progresses, the potentials and functional 
mechanism(s) of protein acetylation remain largely unknown.  The most frequently 
reported mechanism by which HDAC inhibitors (HDACi) acted through was increasing 
“expression of CDKN1A gene, which encodes the cyclin-dependent kinase inhibitor 
WAF1/p21” (169).  Since the acetylation and deacetylation in histone play a critical role 
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in regulating gene expression, the agents that act through interaction with histone 
deacetylases are even more attractive in therapeutic field, especially in cancer therapy.  
As most studies showed that the regulation of histone acetylation and deacetylation was 
generally defective in various cancers (169, 174), therefore, correction of such 
deregulation of histone modification by corresponding agents may potentially be 
promising in cancer therapy.  HDACi are under rapid development for treating various 
diseases, especially for cancer therapy (167, 172).  Currently, more than 14 HDACi are 
under different phase of clinical trials.  Among these HDACi, SAHA is most 
extensively investigated and the first HDACi that has been approved for the treatment 
of cutaneous T cell lymphoma by Food and Drug Administration in the US (171, 172, 
175, 176).  According to the literature, the mechanisms by which HDACi act through 
are involved in many different pathways including alteration of gene expression and cell 
cycle, activation of death pathway, interruption of HDAC function and others. The 
combination of HDACi with other antitumor therapy such as chemotherapy and 
radiation therapy was proposed and extensively investigated.  Accordingly, HDACi 
demonstrated additive or synergistic effect in these combination therapies (172).  
Despite these enhanced therapeutic efficacy, some studies have also reported that the 
resistance to HDACi was developed during the treatment.  Further studies identified 
that the mechanisms were involved in Bcl-2 antiapoptotic protein and multiple drug 
resistance protein (P-gp) (167).  The understanding of the underlying molecular 
mechanisms by which tumor cells resist or respond to HDACi is obviously very 
important for developing therapeutic strategies to effectively target cancer cells.      
       An increasing number of reports demonstrated that EGFR was subject to various 
PTM that were associated with diversified EGFR function (27, 51, 177).  Recent studies 
showed that EGFR was involved in mutations and extensive PTM over the course of 
 14
tumor development, for example, phosphorylation and ubiquitination. The gain-of-
function of EGFR mutations renders high phosphorylation and activation to EGFR in 
NSCLC.  This type of EGFR constitutive phosphorylation renders a subset of NSCLC 
patients bearing such mutations sensitive and/or responsive to a receptor tyrosine kinase 
inhibitor gefitinib (1, 5, 107) and ionizing radiation (22, 24).  Other independent studies 
demonstrated that EGFR was ubiquitinated in three differentiate ways, namely mono-, 
multi-, and poly-ubiquitination. Ubiquitination of EGFR controlled its function, 
localization, and protein stability in cellular processes (22, 27).  Clearly, on the one 
hand, phosphorylation and ubiquitination of EGFR confer EGFR to perform distinct 
function in response to different environmental stimuli.  One the other hand, these 
modifications control protein localization, half-life, and turnover.  During the time I was 
writing this dissertation, acetylation of EGFR was reported, in which demonstrated that 
acetylation of EGFR at lysine 1155, 1158, and 1164 was critical for recruiting AP-2 
protein and regulating EGFR endocytosis (178).  Together, the different EGFR 
modifications are reconciling to maintain cellular balance and homeostasis and 
participating in the regulation of cell behavior and physiological function.  The loss of 
balance in EGFR modifications will cause pathological consequences.  Although these 
advanced studies led scientists to develop therapeutic drugs such as humanized 
antibodies (Cetuximab or C225) and small molecular inhibitors (erlotinib, gefitinib, and 
lapatinib) to target various cancers with the altered EGFR, the underlying molecular 
mechanism(s) and signaling network modulation of EGFR modifications remain elusive 
in cellular and malignant development.  There is still urgent in need of effective drugs 
and strategies to treat various cancers related to EGFR alteration.  Recently, using 
HDACi to treat EGFR-expressing cancer was proposed.  However, inconsistent results 
had also been reported from different research group.  There is a report which 
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demonstrated that using HDACi to treat EGFR-expressing cancer cells increased EGFR 
phosphorylation (179).  Considering HDACi worked as inhibitors of deacetylases that 
could be located in the cytoplasm such as HDAC6 (169), we postulated that not only 
histone proteins but some cytoplasmic proteins might be subject to the modifications of 
acetylation and deacetylation, which were involved in such enhanced EGFR 
phosphorylation.  Therefore, EGFR might be a target for protein acetylation in this 
regard and subsequently participated in signaling networks and cellular processes. 
Based on this anticipation, we hypothesized that additional protein modifications likely 
participate in the regulation of EGFR function besides phosphorylation and 
ubiquitination. These undisclosed EGFR modifications may serve as a part of signaling 
network and cascades dominated by protein phosphorylation.  The function of the 
modifications may enhance or reduce EGFR signaling and function in such a system.  
In addition, we can not rule out the possibility of independent signaling pathway 
regulated by protein acetylation and deacetylation.  In a word, the complexity of EGFR-
regulated cellular function and its metabolism is probably much more pronounced than 
previously thought.   
 
1. 3 EGFR signaling pathways in tumorigenesis 
       EGFR is one of the most well studied receptor tyrosine kinases (RTK).  Since this 
cell surface molecule plays an essential and fundamental role in dictating cell 
proliferation and differentiation, cell cycle control, biological development, 
tumorigenesis, and malignant development (180-182), it has been extensively 
investigated in all aspects of biomedical researches. EGFR regulates many signaling 
pathways including JAK-Stat3/5, PI3K-Akt, and MAPK kinase pathways (1, 5, 21, 22, 
183, 184).  As a traditionally accepted concept, upon ligand stimulation, EGFR forms 
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homodimer or heterodimer with one of other three family members in physiological 
condition (Figure 1), which subsequently results in phosphorylation of EGFR by either 
Src kinase or autophosphorylation.  However, recent study demonstrated that high local 
EGFR concentration could activate EGFR and form dimers, which resulted in EGFR 
phosphorylation (16). The phosphorylated EGFR provides docking sites for binding 
downstream adaptor proteins and thereafter activates several downstream signaling 
pathways.  Upon Src-induced phosphorylation of Y845 on EGFR, the phosphorylated 
Y845 serves as docking site to recruit Stat3/5 and subsequently phosphorylates Stat3 
and/or Stat5, which form homo- or hetero-dimers. The dimerized Stat3 or Stat5 
translocates into the nucleus and regulates cell proliferation, differentiation, cell cycle, 
and migration (Figure3).  Src-activated signal pathway through Y845 is so called 
transphosphorylation activation pathway. Another EGFR activation pathway is 
autophosphorylation signal pathway. EGF ligand stimulation also causes 
autophosphorylation of EGFR.  Several tyrosine residues in intracellular domain of 
EGFR such as Y992, 1068, 1086, and 1173, provide docking sites for adaptor proteins 
such as Shc, Grb2, and Gab and result in the activation of PI3K/Akt and Ras/MAPK 
signaling pathways (21). The activation of PI3K/Akt and /or Ras/MAPK pathways has 
been linked to various cancers (180, 185, 186).  Depending on specific cell types or 
environment, one of these pathways may dominate or all of these pathways equally 
contribute to cellular processes. As far as the interrelationship between 
transphosphorylation and autophosphorylation of EGFR, different observations have 
been reported. One of these studies demonstrated that Src-regulated EGFR 
transphosphorylation acted independently of its autophosphorylation by using in vitro 
cell-based assays (187).  Specifically, this study showed that although EGFR-Y845F  
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Figure 3 EGFR-regulated signaling pathways 
Upon binding to EGF, EGFR is phosphorylated and activates three major downstream 
signal pathways, namely STAT, Akt, and MAPK pathways, which promote cell growth, 
cycle, and malignancy. Meanwhile, the phosphorylated EGFR is subject to ubiquitin-
proteasome dependent degradation that attenuates EGFR signaling.   
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mutant resulted in the loss-of-function of EGFR-regulated cell growth and 
tumorigenesis, there was no alteration of EGFR kinase activity and MAPK activation, 
suggesting the independence of two types of EGFR phosphorylation activations. On the 
contrary, another study demonstrated that EGFR-Y845F mutant resulted in a decrease 
in EGFR phosphorylation at Y1068 which is an important tyrosine site of EGFR that 
regulates MAPK signal pathway (188).  Using Src inhibitor, PP2, phosphorylation of 
Y1068 on EGFR was also reduced, suggesting that two types of EGFR activations are 
intrinsically correlated and interacted.  However, there is no strong evidence that clearly 
demonstrates whether both phosphorylation activations affect and interact with each 
other. The interaction between transphosphorylation and autophosphorylation of EGFR 
is still ambiguous and controversial.  A clear understanding of both phosphorylations on 
EGFR is essential for deciphering its function and targeting EGFR-expressing cancers 
such as lung cancer, breast cancer, and colorectal cancer.   
      Meanwhile, EGFR signaling pathways are also negatively regulated by 
phosphatases such as PTP1B and SHP1 and proteasome-dependent degradation (40, 
189).  Among these negative regulators, the phosphatases can effectively remove 
phosphoryl moiety from EGFR and downregulate EGFR activity. According to the 
literature, PTP1B regulates EGFR autophosphorylation mediated by phosphorylated 
Y992 (190, 191).  SHP-1 attenuates EGFR activity mediated by phosphorylated Y1173 
(56).  Another negative regulation is protein ubiquitination that is Y1045 
phosphorylation-dependent modification.   Phosphorylation of EGFR at Y1045 triggers 
Cbl-mediated ubiquitination and induces EGFR ubiquitination and proteasome-
dependent protein degradation (49, 177, 192).  The regulation of EGFR phosphorylation 
and activation by both positive and negative processes together maintains the 
physiological function of EGFR and controls cell behavior.   
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        Besides cytoplasmic signal transductional function, recent studies showed that full- 
length EGFR could directly translocate into the nucleus and form complexes with 
transcription factors such as Stat3, which regulated transcription and cellular function 
(75, 183).  In addition, increasing evidence shows that EGFR nuclear translocation is 
involved in resistance to chemotherapy and radiation therapy (24, 72, 193-195).  In 
summary, the function of both cytoplasmic and nuclear EGFR demonstrates a critical 
role in regulating cellular processes.  Deregulation of EGFR signaling pathways causes 
severe healthy problems including cancers. The aberrant expression and activation of 
EGFR are frequently detected in cancers of the lung, breast, ovary, skin, brain, and head 
and neck (5, 196).  In addition, Deregulation of EGFR function is also associated with 
diseases of the skin, brain, heart, eye and vision, and renal (79, 104).   EGFR-mediated 
signaling pathways are also involved in many biological processes such as embryonic 
development, DNA repair, chromatin remodeling, anti-apoptosis, malignant 
development and metastasis (22, 83, 180-182).   
       In summary, there are two distinct portions of EGFR signaling pathways, namely 
cytoplasmic and nuclear pathways (Figure 2).  In cytoplasmic signaling pathway or so 
called canonical pathway, EGFR is activated from cell membrane and sequentially 
phosphorylates downstream molecules which pass final growth signals into the nucleus 
and regulate gene expression.  In nuclear pathway, however, EGFR could be directly 
shuttled into the nucleus with whole molecule and participated in the regulation of gene 
expression.  The two pathways seem to have differential regulatory roles in this regard.   
The canonical cytoplasmic pathway most frequently regulates cell growth and cell cycle 
(183), while the nuclear signal pathway is often associated with resistance to therapeutic 
interventions for cancer therapy (70). 
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1. 4 EGFR is a common target for treating various cancers  
       Membrane receptor tyrosine kinase (RTK) family proteins are first layer of 
biological sensors which sense environmental changes in which a cell resides.  
Generally speaking, the current characterization of RTK function is predominantly 
focusing on phosphorylation and ubiquitination that correspond to the cellular events. 
Therefore, for cancer treatment, the agents that target protein phosphorylation and 
ubiquitination have become the mainstream medicine in therapeutic regimens.  Since 
EGFR plays an essential and fundamental role in regulating cell proliferation, 
differentiation, cell cycle, and migration, it is one of the most attractive targets for 
developing anti-cancer drugs (40).  Several common accepted approaches and strategies 
have been proposed in therapy and drug development.  First, antagonizing EGFR 
binding ligands such as EGF and HB-EGF (197).  However, this approach virtually 
requires to develop an individual ligand specific inhibitor that blocks each targeted 
ligand for binding to EGFR.  In addition, off target events could result in severe side 
effects. These drawbacks limit the feasibility of this application in practice.  Second, 
targeting ligand binding domain located at extracellular domain of EGFR (115, 198, 
199).  The successful case is that using EGFR humanized monoclonal antibody (McAb) 
competes to its ligand binding domain and blocks ligand to access to EGFR.  The 
advantage of this approach is the need for only one specific antibody to block a group of 
ligands that share the same binding sites on EGFR, which makes this approach more 
attractive and cost effective.  The third approach is to target the downstream signal 
molecules in EGFR-regulated pathways.  In this approach, the core modulators in the 
pathway need to be identified before effective blockade of the EGFR pathways.  
Unfortunately, in reality the core modulators are difficult to identify.  In addition to this, 
protein network and sequential activations are always involved in EGFR signaling 
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pathways. Therefore, combination therapy will be needed. Lastly, targeting intracellular 
domain of EGFR, usually tyrosine kinase domain. This approach generally uses small 
molecule inhibitors that can penetrate through cell membrane into the cytoplasm then 
perform their anti-EGFR function.  Currently, these newly developed inhibitors 
generally bind to ATP binding sites and consequently inhibit EGFR activity.  Since first 
small molecule inhibitor imatinib was developed to inhibit Abl kinase and was 
approved to treat chronic myelogenous leukemia (200, 201), this area is under rapid 
development and an increasing number of EGFR small molecule inhibitors have been 
developed and approved for treating various human cancers.  Several clinical used 
drugs including humanized monoclonal antibody (Cetuximab or C225) and small 
molecular inhibitors (gefitinib, erlotinib, and lapatinib) exhibit their anti-EGFR function 
by blocking either its dimerization or ATP binding to kinase domain.  Currently, 
humanized anti-EGFR monoclonal antibodies have been rapidly developed to treat 
EGFR-associated diseases including cancers of the lung, breast, brain, and colon.  These 
antibodies demonstrated high effectiveness and efficacy to inhibit EGFR oncogenic 
function in the treatment of certain types of EGFR-expressing cancers.  The working 
mechanisms act through either blocking ligands for binding to EGFR in extracellular 
portion and/or EGFR dimerization in intracellular domain.  No matter what mechanisms 
these antibodies act through, these agents are potent to prevent EGFR activation.     
       Since first successful treatment of NSCLC by using small molecule receptor 
tyrosine kinase inhibitor gefitinib was reported (1), many anti-EGFR small molecule 
inhibitors have been developed recently.  However, through unknown mechanism(s), 
EGFR-expressing cancer cells can still manage to escape the blockade by these agents 
and become resistant to these reagents.  The possible reason, at least in part, is that 
EGFR has gone through genetic, epigenetic, and/or protein posttranslational changes in 
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response to stimuli, and then adapts to new environment and becomes tolerant to these 
therapeutical agents.  For example, the EGFR variant III mutant (EGFR vIII) that does 
not require for ligand can constitutively form dimmer and activate its downstream 
survival signaling in various cancers. This mutant resists to C225 McAb treatment (202-
205).  As far as the effectiveness of targeting EGFR-associated cancer by TKI, studies 
have shown that somatic mutations and deletion in EGFR play a critical role in EGFR 
TKI sensitivity or resistance in the EGFR-expressing cancer cells (5).  Accordingly, 
some somatic mutations of EGFR render certain types of cancer cells bearing such 
mutations sensitive to anti-EGFR inhibitors.  For example, L858R point mutation or Del 
L747-P753 insS in EGFR rendered NSCLC sensitive to gefitinib (5, 21).  Further 
studies suggested that only this subset of patients bearing these mutations responded 
well to tyrosine kinase inhibitors.  In addition, genetic studies showed that people of 
Asian origin without smoking history often carried a high rate of mutation or deletion in 
EGFR in NSCLC (about 30%).   However, there is a relative low mutation or deletion 
rate in EGFR in Caucasian group (about 10%), which explained low response rate to 
gefitinib treatment among Caucasian patients.  Further studies on the molecular 
mechanism unveiled that these somatic mutations or deletions actually augmented 
EGFR phosphorylation at several critical tyrosine phosphorylation sites that elevated 
EGFR activity with unidentified reasons (5, 21).  Of the EGFR-regulated signaling 
pathways, MAPK signaling pathway was mainly involved upon the treatment with TKI.  
However, depending on cell types, other pathways such as Stat and PI3/Akt might be 
also involved to respond to TKI.  Although these TKI such gefitinib theoretically act 
through blocking the EGFR ATP binding site that consequently inhibits EGFR activity, 
these studies only demonstrated phosphorylation of EGFR was reduced but no evidence 
that showed whether EGFR kinase activity was altered in the presence of TKI.  In 
 23
addition, very often, cancer relapses shortly after initial response due to acquiring 
second mutation T790M on EGFR, which results in resistance to these EGFR inhibitors 
(206). Therefore, clinical applications by using these inhibitors are limited and only 
effective to a specific subset of cancer patients with a limit period of time. We view 
these alterations of EGFR by genetic, epigenetic, and protein modifications as critical 
mechanisms by which EGFR-mediated cancer cells evolutionarily adapt to 
environmental pressure and challenges. This adaption provides survival advantages for 
EGFR-expressing cancer cells.   Therefore, study for EGFR alterations in these cancer 
cells may possibly provide biomarkers for diagnosing cancer and predicting prognosis 
and will likely lead to more insights for developing more advanced and effective drugs 
that target EGFR-associated cancers.   
       In addition, the development of agents acting on EGFR ubiquitination is ongoing 
and exhibits potential for clinical applications (207). However, little is known about the 
role of whether or how EGFR ubiquitination plays in cancer development or cancer 
therapy.  With respect to HDACi, recent studies demonstrated that HDACs such 
HDAC6 participated in EGFR regulation and turnover (208, 209).  Therefore, targeting 
EGFR interacting HDAC by HDACi was proposed accordingly.  Moreover, a variety of 
therapeutic approaches and agents that aim at EGFR associated adaptor proteins, signal 
proteins, and chaperon proteins are under development as well (210, 211).  All in all, 
suggesting that EGFR is an attractive target in the treatment of various diseases.     
 
1. 5 Development of combination therapy for targeting EGFR-associated 
cancers 
       Traditional approaches for treating cancers are including chemotherapy and 
radiation therapy. In the treatment of EGFR-expressing cancers, the resistance to these 
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conventional therapies is a major problem that needs to be tackled in the clinic. A 
number of studies demonstrated that several mechanisms could result in such resistance.  
Among those, EGFR alteration and localization played an important role in these 
therapies.  EGFR mutation was reported to link with sensitivity or resistance to 
antitumor drugs, chemotherapy or radiation therapy (5, 206).  For example, EGFR vIII 
was reportedly associated with resistance in the treatment of glioblastoma multiforme 
by chemotherapy or radiation therapy (212-214).   An increasing number of reports 
demonstrated that EGFR shuttling and nuclear localization contributed to resistance to 
these conventional therapies as well (193).  Therefore, the understanding of underlying 
mechanisms by which EGFR-expressing cancers develop resistance to these 
conventional therapies will obviously be critical in the treatment of relative cancers.   
With respect to newly developed antitumor agents, anti-EGFR drugs including 
humanized antibodies and small molecule inhibitors that have been developed show to 
some extent efficacy for the inhibition of tumor growth and survival.  However, cancer 
cells rapidly develop resistance to these drugs and relapse, typically within a year or so 
(215-217).  A typical case is dramatic responsive to gefitinib in a subset of NSCLC 
patients. The population of approximately 10% Caucasian or 30% Asian women with 
non-smoking history showed dramatic response to gefitinib in the treatment of NSCLC.  
Further investigation demonstrated that these patients exclusively carried somatic 
mutations in EGFR, most significantly, L858R point mutation in exon 21 and/or 
deletion L747-P753 insS in exon 19 accounted for over 80% of responders among those 
patients.  However, cancer relapsed after 6 months later that was mostly resulted from 
the acquisition of second T790M mutation so called “gate-keeper mutation”.  Upon this 
mutation occurred, the patients became resistant to gefitinib treatment (206).  A great 
deal of effort was engaged in developing new generation of irreversible TKI, which 
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attempt to overcome mutation-acquired resistance.  It appears that cancer cells seem to 
have intrinsic mechanisms that adapt to environmental challenges and eventually alter 
their cell behavior that resists to various interventions.  Several theories were proposed 
to explain cancer cell adaption.  One of accepted theories is called oncogene addiction 
concept (218).  In this theory, the cancer cells generally have more than one oncogene-
regulated survival pathways that may be equally depended. The downregulation of one 
cancer cell survival pathway by antitumor agents will eventually lead to affected cells 
more dependent on another surrogated pathway to survive.  This is so called acquired 
dependency.  The blockade of such a surrogated pathway will lead to the lethality of the 
affected cancer cells.  Such cancer cells become more vulnerable to antitumor agents 
that target this surrogate survival pathway, which is rationale for combination therapy to 
treat underlying cancers.    Another theory is that heterogeneity of cancer cells that 
makes cancer cells not only more difficulty to treat with a single regimen but also rapid 
to develop resistance to these agents (210, 219, 220).  In this regard, the combination 
for simultaneously targeting multiple cancer cell survival pathways could be more 
effective and least likely to develop resistance.    No matter what theory can be adapted 
to explain this cancer resistance, a number of observations have demonstrated that the 
combination therapy seems more effective approach for cancer therapy and becomes 
trend for future cancer therapy.  Moreover, due to the heterogeneity of cancer cells, the 
phenotype of an individual patient is ununified.  This characteristics of cancer cells also 
makes the gene expression profile in an individual cancer patient different from each 
other.  Therefore, personalized therapy was proposed in order to deal with such a 
complexity (120, 121). 
       A various combinations of antitumor agents have been proposed and applied in 
different phases of clinical trials (210, 221, 222).  While developing new generation of 
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anti-cancer drug is a time- and money-consuming task, we consider that it is a feasible 
and economical way to combinatorially utilize current available anti-EGFR drugs to 
treat related cancers.  Given sensitization effect of EGFR mutations in lung cancer to 
various inhibitors, we hypothesize that protein modifications of EGFR are the key 
events to target in the treatment of EGFR-expressing cancers. The investigation of 
EGFR additional modifications will provide insights and rationale for possible 
combinatory therapy.  A growing number of proposed clinical trials for combined 
therapeutic regimens to treat various EGFR-associated cancers are under developing.  
These ongoing trials, to some extent, show potentials and benefits to cancer patients 
(126).      
 
1. 6 Hypothesis, rationale, and significance  
Hypothesis 
       1. EGFR is likely regulated in the early stage prior to ligand stimulation by protein    
          PTM.  
       2. EGFR functioning may depend on its modifications through genetic, epigenetic,   
           and protein modifications.  Therefore, additional EGFR PTM may exist and      
           play a role in the regulation of EGFR function. 
       3. EGFR PTM may be linked to therapeutical efficacy in the treatment of  
           EGFR-associated diseases.   
 
Rationale 
       We found EGFR lysine acetylation by using an anti-acetyl-lysine antibody. In 
A431 cells treated with a deacetylase inhibitor, EGFR acetylation and phosphorylation 
were enhanced simultaneously.  Considering the fact that deacetylase inhibitors elevate 
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EGFR phosphorylation by our own observations as well as  literature reports (179, 221), 
we speculate that EGFR acetylation may play an important role in cell survival and 
growth.  However, due to oncogene addiction effect, HDACi-induced EGFR activation 
could lead cancer cells more susceptible to EGFR tyrosine kinase inhibitors such as 
erlotinib, gefitinib, and lapatinib.  Therefore, combination of HDACi and EGFR 
inhibitor may benefit for the treatment of cancers associated with aberrant expression of 
EGFR.   
 
Significance 
       This study provides experimental evidence and a molecular mechanism by which 
HDACi induce EGFR phosphorylation and activation.  We found that EGFR was 
acetylated by CBP in the early stage of EGFR activation.  Acetylation of EGFR could 
enhance its phosphorylation and activity.  Meanwhile, HDACi-induced EGFR 
phosphorylation may provide cell growth advantage and contribute resistance to 
HDACi.  Our study suggest that the combination of EGFR inhibitors and HDACi could 
benefit for the treatment of cancers associated with aberrant expression of EGFR.   
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2.1   Cell lines and chemicals  
      A431, A549, H3255, Hela, HEK293, MCF7, MDA-MB-453, MDA-MB-468, and 
T47D cells were purchased from ATCC and cultured according to ATCC’s instructions.  
In general, the cells were cultured using DMEM containing 10% fetal bovine serum 
with 200 g/ml penicillin and 200 g/ml streptomycin in a 5% CO2 incubator.  HBE4 
cells were cultured with serum-free medium.  The medium was changed every 2-3 days.  
The cells were used for following experiments.  All chemical reagents were purchased 
from Sigma or Fisher Scientific companies, respectively and are analytical grade except 
as otherwise noted (223). 
 
2.2   Plasmids for expression of proteins 
       pcDNA6A-EGFR and pcDNA6A-EGFR-K3R (the Myc and His tagged vector) 
were constructed for expression of EGFR and EGFR-K3R mutant, respectively.  The 
plasmids for expression of CBP, p300, and PCAF (CBP and PCAF are flag-tagged and 
p300 is HA-tagged) were generous gifts from Drs E.Y. Chin (Brown University) and 
T.P. Yao (Duke University).   The plasmid for expression of Src was generously 
provided by Dr. G.E. Gallick (UT/MDACC) (223). 
 
2.3   Antibodies 
       Antibodies were purchased from companies as follows: Polyclonal anti-acetyl-
lysine and monoclonal anti-phospho-tyrosine (4G10) antibodies were purchased from 
Upstate Biotechnologies Incorporation, USA.  Polyclonal anti-EFGR, anti-p300, and 
anti-CBP antibodies were purchased from Santa Cruz Biotechnologies Incorporation, 
USA.  siRNA for knockdown of CBP, p300, and EGFR was obtained from Santa Cruz 
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company as well.  Polyclonal anti-phosho-Erk, anti-Erk, anti-phospho-Akt, anti-Akt, 
anti-phospho-Stat3, and anti-Stat3 antibodies were purchased from Cell Signaling 
company, USA.  Monoclonal anti-EGFR antibody (AB13) was obtained from 
NeoMarkers, USA. Anti-Src antibody (monoclonal Ab) was purchased from 
CalBioChem, USA (223).   
       To detect an individual EGFR acetylation, in collaboration with China Medical 
University, Taiwan, we generated an antibody against acetylated EGFR-K843 site. The 
peptide sequence for generating antibody was: RNVLVKTPQHVKITDFGLA 
KLLGAEE-K-EYHAEGGKVPIKWMALESILHR. Briefly, anti-acetyl-EGFR-K843 
antibody was generated by injecting the acetylated peptide corresponding to the K843 
site (synthesized by Quality Controlled Biochemicals, USA) into mice with boosting 
injection every 2 weeks.  The sera were collected for Western blot analysis.  For 
eliminating background, non-acetyl-peptide against K843 site (250 ng/ml) was added to 
block non-specific reaction.  This antibody can be used for detecting endogeneous 
EGFR acetylation in various cell types.   
  
2.4   Site-directed mutagenesis and PCR 
       Ultra-Blue site-directed mutagenesis kit was purchased from Stratagene, USA. The 
mutations were performed based on standard procedures and manufacturer’s 
instructions. The mutation primers: 5’-CAGATTTTGGGCTGGCCAGACTGCTGGGT 
GCGGAAG, 5’-CTTCCGCACCCAGCAGTCTGGCCAGCCCAAAATCTG, 5’-CAG 
ATTTTGGGCTGGCCAGACTGCTGGGTGCGGAAG, 5’-CTTCCGCACCCAGCAG 
TCTGGCCAGCCCAAAATCTG,  5’-GCTCTCTTGAGGATCTTGAGGGAAACTGA 
ATTCAAAAAG, and 5’-CTTTTTGAATTCAGTTTCCCTCAAGATCCTCAAGAGA 
GC were synthesized by Sigma and used for generating EGFR-K3R mutant.  The 
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EFGR-K3R mutant was confirmed by DNA sequencing at MD Anderson Cancer Center 
Sequencing Core Facilities (223). 
 
2.5   Generation of stable clones for expression of EGFR or EGFR-K3R  
       MCF7 or HEK293 cells were seeded on 10 cm culture plates and cultured in 
DMEM with 10% FBS and appropriate antibiotics one day prior to transfection.  On the 
second day, the cells reached to 90-95% confluence and were ready for transfection.  
The plasmid for expression of either EGFR or EGFR-K3R was pre-diluted in 0.5 ml 
Opti-MEM transfection medium at a final concentration of 16 g/ml in a 15 ml tube.  In 
a separate tube, 20 l of liposome transfection reagent was pre-diluted in 0.5 ml Opti-
MEM medium and incubated for 5 min at room temperature.  Following to mix the 
plasmid with liposome and incubate the mixture for 25 min at room temperature.  The 
cells were rinsed with Opti-MEM and added 4ml fresh Opti-MEM for transfection.  The 
transfection mixture was added into the cells drop by drop with gentle shaking, then the 
cells were cultured for 6h.  After 6h culture, removed transfection medium and added 
10 ml fresh DMEM containing 10%FBS without antibiotics.  After 2 days later, the 
cells were ready for antibiotics selection.  The cells were splitted and selected with 10 
g/ml blasticidin in DMEM containing 10%FBS and appropriate antibiotics.  After 3 
weeks selection, individual clone was selected and continued culturing in DMEM 
containing 5 g/ml blasticidin.  The stable clones were tested for EGFR or mutant 
protein expression by Western blot.  The final clones with appropriate protein 
expression were collected or stored for later analysis and study.    
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2.6   Cell lysate preparation 
        The cells were washed with pre-cold PBS containing appropriate protease 
inhibitors.  After washing, the cells were scratched by a cell lifter in 3ml fresh PBS with 
protease inhibitors, then centrifuged for 5 min at 1000 rpm.  Discarded the supernatant 
and the cell pallets were used for preparation of cell lysates.  RIPA buffer containing 3 
mM PMSF, 3 mM Na3VO4, 3 mM NaF,  3 µg/ml for each of aprotinin, leupeptin, 
pepstatin, 5 mM sodium butyrate, and 20 M TSA.  The cells were suspended and then 
briefly ultra-sonicated. Following to incubate for 15 min at 4ºC with gentle rotation and 
then centrifuged for 20 min at 10,000 rpm. the supernatant was transferred to a separate 
clear tube for immediate experiments or stored at -80ºC for later use.    
       For nucleus fractionation, the cells were lysed by using lysis buffer containing 20 
mM, 10 mM KCl, 2 mM MgCl2, 0.5% NP-40, 1 mM PMSF, and 2 ug/ml Aprotinin.  
After that, the cells were transferred into a Dounce homogenizer and homogenized with 
30 strokes.  Then, centrifuged for 5 min at 4000 rpm.  The nucleus pellets were lysed 
with RIPA buffer as described above.  The lysates can be used for studying nuclear 
portion of proteins (223).   
 
2.7   Immunoprecipitation and immunoblot 
      For immunoprecipitation, a total of 500 g of cell lysate was used and diluted in 
500 l of RIPA buffer containing 3 mM PMSF, 3 mM Na3VO4, 3 mM NaF, 5 mM 
sodium butyrate, and 20 M TSA with corresponding antibodies.  After adding 2g 
either anti-EGFR antibody (mouse monoclonal, NeoMarkers) or anti-Myc antibody 
(Sigma), the mixture was incubated with gentle rotation for 2h at 4 ºC, then added 80l 
of protein-G beads and incubated for additional 2h.  The beads were washed twice by 
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RIPA buffer and 50 l 2x protein loading buffer was added into the beads.  Then the 
beads were heated for 5 min at 100 ºC.  After brief centrifuge, the supernatant was 
loaded on 8% SDS-polyacrylamide gel and proteins were separated under 100 voltage 
power.   
       For immunoblot, a total of 20 g of cell lysate was used and heated by similar 
procedures as mentioned above, and following separated on 8% SDS-PAGE.  Then, the 
proteins separated by SDS-PAGE were transferred to a PVDF membrane and probed 
with antibodies as indicated in Figures.  The immunoblot and image capture were 
performed following standard procedures (223).    
 
2.8   Nano-HPLC-MS/MS spectrophotometry 
       A431 cells were cultured in 10 cm plates in DMEM with 10% FBS and appropriate 
antibiotics.  After reaching to 90% confluence, the cells were treated with 2 M TSA 
and 5 mM sodium butyrate for 24h.  On the second day, the cells were treated with 25 
ng/ml EGF for 5 min prior to collection.  The cells were lysed by RIPA buffer with 3 
mM PMSF, 3 mM Na3VO4, 3 mM NaF, 3 µg/ml of aprotinin, leupeptin, and pepstatin, 
respectively, 5 mM sodium butyrate, 20 M TSA, and 20 mM Nicotinamide and the 
procedures were followed as mentioned previously.  Especially, for preserving EGFR 
acetylation, TSA and sodium butyrate are essential for inhibiting HDACs to deacetylate 
EGFR.  The 5 mg of cell lysate extracted from pretreated A431 cells was 
immunoprecipitated with an anti-EGFR monoclonal antibody (NeoMarkers). After 
washing, the mixture was resolved on 8% SDS-polyacrylamide gel.  The separated gel 
bands were excised and subject to in-gel trypsin digestion, then analyzed by nano-
HPLC-MS/MS system (124, 223, 224).  
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2.9   Transfection of plasmid or siRNA into mammalian cells 
      wt-EGFR or EGFR-K3R was transfected by liposome, respectively.  Co-
transfection of EGFR or EGFR-K3R with either p300 or CBP or PCAF was also 
performed by using liposome followed procedures as mentioned previously.  Briefly, 
eight g plasmid for expression of target protein was transfected into the cells using 
liposome.  After transfection, the cells were allowed to express for 48h prior to 
collecting the cells for protein expression analysis.   
       The transfection of siRNA for knockdown of p300, CBP, and EGFR was employed 
by using electroporation.  The reagent for electroporation was purchased from Amaxa, 
Germany.  The transfection was followed manufacturer’s instructions.  In brief, either 
A431 cells or MDA-MB-468 cells were trypsinized and washed in pre-cold PBS.  The 
cells were re-suspended in 200l transfection solution and 100 nM siRNA.  Then 
transfection procedures were performed by employing an Amaxa electroporator 
(Nucleofector I, Germany).  The cells then were cultured for 72h prior to assay.  After 
72h culture and expression, the cells were collected for protein expression analysis by 
Western blot.   
 
2.10   Immunofluorescence assay 
       The cells for immunostaining were seeded in a chamber slide and cultured for 24h 
and subject to serum-starvation for additional 24h prior to assay.  The cells were then 
treated with 25 ng/ml EGF for 30 min prior to immunostaining.  After treatment, the 
cells were washed twice in pre-cold PBS. Then, the cells were fixed by 4% 
paraformaldehyde for overnight.  On second day, discarded fixation solution and 
washed the cells twice in pre-cold PBS.  After washing, added blocking buffer 
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containing PBS with 3% BSA and 2% Triton X-100 and incubated for 2h at room 
temperature.  Removed blocking buffer and added the first antibody diluted in PBS with 
2% Triton X-100 and incubated for 2h at 4 ºC.  Washed the cells twice in PBS and 
added the second antibody conjugated with fluorescence (FITC) and incubate for 1h at 
room temperature.  Following to wash the cells three times in PBS and the slide was 
sealed using nail solution for observation by confocal microscopy.    
 
2.11   Assay for protein dimerization  
       wt-EGFR or EGFR-K3R was transfected into HEK293 cells by liposome, 
respectively.  After 48h expression, the transfectants were serum starved for 24h and 
then treated with 25 ng/ml EGF for 5 min.  Washed the cells twice using pre-cold PBS 
and added cross-linking reagent BS3 [Bis (sulfosuccinimidyl) suberate salt] 1.5 mM in 
PBS, then the ells were incubated for 2h on ice.  After incubation, the cells were washed 
in PBS and collected for assay.  
 
2.12   Cell growth assay 
       For in vitro cell growth assay, 1X104 cells were seeded in a 6-well culture plate in 
DMEM containing 10% FBS and appropriate antibiotics. At specified time points, the 
cells were stained with trypan blue and counted.  At least three independent experiments 
were performed and mean ± standard deviation (SD) was calculated and used for 
comparisons.    
 
2.13   BrdU incorporation 
       For measuring cell DNA synthesis, 1X105 MCF7 cells stably expressing either wt-
EGFR or EGFR-K3R mutant were seeded in 6-well plates.  After 30h serum starvation, 
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the cells were treated with 30 M BrdU (BD transduction) in 10% FBS fresh medium 
with or without 25 ng/ml EGF for 16h, then an anti-BrdU monoclonal antibody 
(Upstate) was used to detect incorporated BrdU substrate in the cells.  A FITC 
conjugated goat anti-mouse IgG antibody (Johnson Laboratory, USA) was used to 
amplify signals. Then DNA incorporated cells were counted by using a fluorescence 
microscope.  At least three independent experiments were performed and mean ± SD 
was calculated and used for comparisons.    
 
2.14   Soft agar assay 
       For anchorage independent cell growth assay, preparing 1.6% agarose solution in 
PBS and mixing equal volume of agarose and 2x DMEM containing 20% FBS and 
antibiotics.  Added the mixture into a 6-well culture plate and let mixture become solid 
0.8% bottom supporting gel.  Then, 5x104 cells were resuspended into 2X DMEM 
medium including 20% FBS and appropriate antibiotics and then mixed with an equal 
volume of 1.0% agarose gel.  Finally, the mixtures were seeded in the 6-well plate on 
the bottom supporting gel.  The cells were feed every 2-3 days with DMEM containing 
10% FBS with appropriate antibiotics. The colonies were formed and counted after 
culturing for two consecutive weeks.  At least three independent experiments were 
conducted and mean ± SD was calculated and used for comparisons.    
 
2.15   Cell viability assay 
       To test the effect of drugs on tumor cell killing, 1X104 cells were seeded in a 96-
well plate and cultured for 24h.  Then, treated with either SAHA or TKI (erlotinib, 
gefitinib, lapatinib) or different combinations as indicated for 72h.  After that, added 
 37
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to a final 
concentration of 0.5 mg/ml and continued culturing for another 2-4h.  Then 100 l of -
isopropanol was added into each well to dissolve precipitated substrate.  Optical density 
(OD) was measured by a microplate reader (Bio-Rad, U.S.A.). At least three 
independent experiments were conducted and mean ± SD was calculated and used for 
comparisons (223).    
 
2.16   Flow cytometry 
      To study the effect of HDACi on cell cycle, 1X105 cells were seeded in a 6-well 
culture plate.  After treatment, the cells were washed twice in pre-cold PBS and fixed 
by 50% ethanol for incubated for 1h at -20 ºC.  Then the cells were centrifuged and the 
supernatant was removed.  Following to add 500 l propidium iodide to a final 
concentration of 10 g/ml.  The cells were analyzed by flow cytometry.   At least three 
independent experiments were conducted and mean ± SD was calculated and used for 
comparisons.    
 
2.17   In vivo mammary fat pad tumor cell injection 
       The nude mice were grouped randomly.  A 17-estradiol tablet was inoculated 
under the skin of each mouse 3 days prior to tumor cell injection.  To compare the effect 
of wt-EGFR and EGFR-K3R mutant on cell tumorigenesis, 5X106 MCF7 parental cells 
or stable clones were inoculated into mammary fat pad of nude mice.  The tumor size 
was monitored and measured following standard procedures.  Animal manipulation was 
in accordance with institutional guidance and policies.   
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2.18   In vivo animal treatment 
       To test the effect of drug on tumor cell growth in vivo, 5X106 MDA-MB-468 cells 
were inoculated into mammary fat pad of each mouse.  When tumor size reached 100 
mm3, then mice were grouped randomly as placebo or treatment groups.  The treatment 
was initiated at the same day for each group.  SAHA (20 mg/kg) and /or erlotinib (15 
mg/kg) were administrated by oral daily. The tumor size was measured twice per week.  
Animal handling follows institutional policies and regulations accordingly (223). 
 
2.19   Statistical analysis   
       Statistical analyses were performed by student’s t-Test and ANOWA analysis.  All 
data are described as mean ± SD.  In general, P<0.05 is considered as statistical 
significance (223).   
 
2.20   Clinical trial information 
       The list of ongoing clinical trials about HDAC inhibitors for the treatment of a 
variety of cancers can be found at: http://www.cancer.gov/clinicaltrials 
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CHAPTER 3   RESULTS 
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3 .1   Defining the role of EGFR acetylation 
 
3.1.1 Identifying EGFR acetylation  
       It has been reported that HDACi induced EGFR phosphorylation.  We considered 
that this effect might link with tumor cell resistance to HDACi (179). Recent studies 
demonstrated that EGFR interacted with HDAC6 in tumor cells that express EGFR 
(208, 209). Therefore, it is of interest in investigating likelihood of EGFR acetylation.  
Since A431 cells overexpress EGFR, this characteristics makes them as excellent 
candidates for studying EGFR modifications.  By using A431 cells that are widely used 
cancer cells for studying EGFR function, we performed immunoprecipitation assay by 
immunoprecipitating (IP) with an anti-EGFR antibody and immunoblotting (IB) with an 
anti-acetyl Lysine antibody.  EGFR acetylation was clearly demonstrated as showed in 
Figure 4A.  And vice versa, in reciprocal immunoprecipitation by IP with an anti-
acetyl-Lysine antibody and IB with an anti-EGFR antibody, we found similar results as 
showed in Figure 4A.  In addition, an HDAC inhibitor, TSA, further enhanced 
acetylation of EGFR as showed in figure 4B.  Together, these results suggest that EGFR 
acetylation occurred endogenously and was biologically meaningful PTM.  This finding 
raises the question of whether or not EGFR acetylation is a universal modification in 
EGFR-expressing cancer cells.  Is EGFR acetylation a common way that the cells adapt 
to environmental stimuli and/or cellular changes in order to survive?   To address this 
question, we examined various EGFR-expressing cancer cell lines and fund that EGFR 
acetylation could be detected in various EGFR-expressing cancer cells (data not 
shown).  This result suggests that EGFR acetylation may be a common phenomenon in 
cellular processes.   
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3.1.2 Determining acetylation sites of EGFR 
        Next, we worked on the enrichment of EGFR acetylation in order to identify 
acetylation sites, which is the most important step to understand the function of EGFR 
acetylation.  There are two major approaches to address this issue.  1) MS/MS 
technique. 2) Mutation and deletion approach.  MS/MS is current the most powerful and 
effective methodology to determinate protein modifications such as phosphorylation, 
ubiquitination, and acetylation. To identify all the possible modification sites, there is in 
need of covering all the peptide in the protein sequence.  Proteolytic peptides behave 
differently during in-gel digestion and in machine. Some peptides respond much better 
than others. Therefore, it is almost impossible to cover 100% of protein sequence. This 
may be one of the possible reasons that we identified different EGFR acetylation sites 
from a report in the literature (178).  In addition, cell type difference could be another 
reason that caused different acetylation of EGFR during the cellular processes.   With 
the combination of MALDI-TOF and nano-HPLC MS/MS, we can reach up to 70% 
identification efficacy (225). Generally, a 3 pmole of protein or greater (appropriately 
0.5 g of EGFR) is helpful to increase sequence coverage and to identify maximum 
number of modification sites.  To enrich such amount of protein, we used 150 mm 
culture plates to culture cells.  To maximize the possibility of identifying EGFR 
acetylation sites, the cells were treated with multiple deacetylase inhibitors as stated in 
the section of Materials and Methods in order to prevent from rapid deacetylation by 
HDACs.  Then, double immunoprecipitation using anti-EGFR and anti-acetyl-lysine 
antibodies was performed to enrich the portion of acetylated EGFR.  Since epidermoid 
carcinoma cell line A431 is highly overexpressing EGFR, we were able to extracted 
sufficient EGFR from A431 cells by using a specific monoclonal antibody against 
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Figure 4  Acetylation of EGFR 
A total of 500 g cell lysate was immunoprecipitated and immunoblotted with 
antibodies as indicated. EGFR acetylation was detected by using a polyclonal anti-
acetyl-lysine antibody. A. A431 cells were cultured in DMEM containing 10% FBS 
and used to analyze endogenous EGFR acetylation.  B.  A431 cells were serum-
starved and then treated with 20 M TSA for 5h prior to collecting the cells.  
(The figure 4 is adapted with permission from Elsevier Ltd) 
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A. K684 acetylation 
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B.  K836 acetylation 
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C. K843 acetylation 
 
 
 
 
 
Figure 5  Acetylation of EGFR at K684, 836, and 843 sites 
A431 cells pretreated with 2 M TSA and 5 mM sodium butyrate for 24h were 
lysed and immunoprecipitated by an EGFR antibody and then were subjected to 
nano-HPLC-MS/MS analysis.  A. Acetyl-K684. B. Acetyl-K836. C. Acetyl-K843. 
(Done by Dr. Yingming Zhao, The University of Texas, Southwestern Medical 
Center, Dallas, TX).   (The figure 5 is adapted with permission from Elsevier Ltd) 
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Figure 6  protein alignment of EGFR 
K843 and Y845 are highlighted in figure.  The alignment was performed by using 
ClustalW.    
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Figure 7  Structure of EGFR kinase domain 
Tyrosine 845 and lysine 843 are showed in this figure.  Both sites are highly conserved 
among various species.  Lysine 684 and 836 are not shown in this figure (Courtesy by 
Dr. Xiaomin Chen, Department of Biochemistry, UT/MDACC).   
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EGFR.  Meanwhile, we carefully enriched and preserved its acetylation by using 
multiple deacetylase inhibitors in all steps of cell and protein processes including 
treating the cells, lysing the cells, and performing immunoprecipitation.  The extracted 
EGFR protein was subject to SDS-PAGE separation.  The gel bands migrating at about 
170 kDa position were excised and subject to trypsin in-gel digestion.  We identified 
three EGFR acetylation sites that were all located in intracellular domain, namely K684, 
836 and 843 (Figure 5).   Based on current available EGFR kinase domain structure, we 
performed computer simulation analysis and identified that K843 and Y845 sites are 
highly conserved and physically close to each other (Figure 6).  Y845 is a very 
important tyrosine phosphorylation site that regulates cell growth, proliferation, and cell 
cycle.  K836 and 843 with Y845 have been reported to form enzymatic pocket that 
determines intrinsic EGFR kinase activity (226).    Taken together, these results suggest 
that EGFR PTM on K836 and 843 along with Y845 may change the structure of this 
pocket and affect protein-protein interactions that subsequently result in change of 
related downstream signal pathways (Figure 7).  The close proximity of three key amino 
acids may be one of reasons that alteration and interruption of protein modification may 
affect EGFR function.  In addition, EGFR acetylation may potentially affect its 
phosphorylation due to the change of this triad including K836, K843, and Y845 sites.   
 
3.1.3 CBP is responsible for acetylating EGFR 
       The following question we need to address is what enzyme(s) acetylates EGFR.  
Since CBP, p300, and PCAF are three well-characterized acetyltransferases and play an 
important role in regulation of gene expression in mammalian cells (227), this fact 
makes them as reasonable and potential candidates for determining the responsible 
enzyme that acetylates EGFR.  Cotransfection of EGFR with either CBP or p300 or 
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PCAF into HEK293 cells was performed.  Immunoprecipitation and immunoblot results 
demonstrated that only CBP dramatically induced EGFR acetylation while p300 and 
PCAF could not induce detectable acetylation of EGFR (Figure 8A).  The knockdown 
of CBP but not p300 by siRNA resulted in significantly reduction of EGFR acetylation 
in A431 cells (Figure 8B).  Acetylation–deficient EGFR-K3R mutant significantly 
reduced EGFR acetylation by CBP in HEK293 cells that ectopically expressed CBP and 
EGFR-K3R (Figure 8C), suggesting that CBP is an enzyme that can acetylate these 
three lysines on EGFR.  Taken together, these data suggest that CBP is the enzyme that 
acetylates EGFR in vivo.  In addition, we observed that CBP could increase EGFR 
tyrosine phosphorylation alongside EGFR acetylation as shown in Figure 8D.  
Moreover, we also demonstrated the interaction between CBP and EGFR (Figure 8E).  
All in all, these data support that CBP is a major acetylase that acetylates EGFR.       
       CBP is CREB binding protein and plays a key role in the regulation of gene 
expression.  CBP is a transcription coactivator that is mainly located in the nucleus.  
The first obvious question is how CBP reaches to EGFR and then acetylates EGFR.  It 
has been reported that there is small percent of CBP that remains in the cytoplasm in the 
non-stimulated cells, although the majority of CBP are mainly located in the nucleus, 
which may explain that EGFR acetylation occurred prior to ligand stimulation.  
However, in response to ligand stimulation, CBP rapidly moved out the nucleus and 
traveled towards cell membrane and then acetylated target proteins (228).  We treated 
24h serum starved A431 cells with 25ng/ml EGF for different time points and then 
performed cellular fractionation for immunoblot analysis and cell immunostaining for 
confocal microscopy analysis.  The data demonstrated that CBP rapidly shuttled out the 
nucleus and moved into the cytoplasm as showed in Figure 9.  Within a short period of 
time, the majority of CBP rapidly moved into the cytoplasm.  This observation is very 
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similar to results reported in the literature (228).  In addition, AG1478, a tyrosine 
inhibitor, was not able to block CBP shuttling from the nucleus into the cytoplasm.  
These suggest that it may be a general phenomenon of which ligand stimulation can 
cause CBP to travel out of the nucleus, then CBP moves towards cell membrane and 
performs its function.  Since both interferon and EGF can trigger CBP shuttling, 
suggesting that this phenomenon is not an EGF-specific event.   
 
3.1.4 Acetylation and protein stability  
       It has been shown that protein PTM, very often, affect protein stability (27, 229-
231).  To address whether EGFR acetylation affects its protein stability, we generated 
HEK293 cell stable clones that expressed either wt-EGFR or acetylation-deficient 
EGFR-K3R mutant.  The stable clone cells were treated with 1 M cycloheximide for 
the time points as indicated in Figure 10.  Then the cells were collected and subjected to 
immunoblot analysis.  Although EGFR-K3R significantly reduced lysine acetylation, 
the protein level of EGFR remained similar to wt-EGFR.  Our observation suggests that 
EGFR protein stability is not significantly affected by EGFR acetylation.   
 
3.1.5 Acetylation and protein dimerization 
       In response to ligand stimulation, EGFR generally forms dimers and then 
subsequently activates downstream signal pathways.  The dimerization of EGFR is the 
key process to activate EGFR and EGFR-regulated downstream pathways. To 
investigate whether EGFR dimerization is affected by EGFR acetylation, HEK293 cells 
expressed either wt-EGFR or EGFR-K3R were treated with EGF, and then artificial 
dimers were formed by using BS3 crossing linker reagent in these cells.  The cells were 
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lysed and analyzed by Western blot.  The gel shifting pattern of both wt-EGFR and 
EGFR-K3R was similar to each other as showed in Figure 11, suggesting that EGFR 
protein dimerization was not affected in acetylation-deficient EGFR-K3R mutant.  This 
observation may further indicate that EGFR acetylation in the intracellular portion of 
EGFR least likely affects EGFR dimerization.  
 
3.1.6 Acetylation and protein trafficking 
       EGFR is subject to frequent endocytosis and shuttling between membrane and 
inside of the cell.  To compare whether EGFR acetylation is associated with EGFR 
protein endocytosis and localization, stable HEK293 cell clones for expression of either 
EGFR or EGFR-K3R were serum starved for 24h and then treated with 25 ng/ml EGF 
for 30 min.  After fixation by ethanol, the cells were immunolabeled with an anti-EGFR 
monoclonal antibody and then detected by using a FITC-conjugated anti-IgG antibody.  
Finally, the cells were observed by a confocal microscopy.  Our data demonstrated that 
EGFR surface protein expression and quantity were similar to each other as showed in 
Figure 12.  In addition, in response to EGF, EGFR distribution pattern and localization 
were virtually no difference between wt-EGFR and EGFR-K3R.  Together, tthese 
results suggest that EGFR acetylation may least likely affect its protein trafficking and 
shuttling.   
 
3.1.7 Acetylation and protein interaction 
       Since K836 and K843 acetylation sites are physically located in the intrinsic 
enzymatic pocket of EGFR (226),  the interruption of acetylation at K836 and 843 may 
intrinsically affect recruitment of EGFR adapter proteins and signaling proteins.  Most  
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(The figure 8A-C is adapted with permission from Elsevier Ltd) 
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Figure 8   CBP acetylase is responsible for acetylating EGFR 
A. wt-EGFR was co-transfected with CBP, p300 or PCAF into HEK293 cells, 
respectively. The cells were cultured for 48h after transfection, then 
immunoprecipitation and immunoblot were performed by using lysates from these 
transfectants.  B.  siRNA for silencing p300, or CBP was transfected into A431 cells 
by electroporation, respectively. The cells were cultured for 72h after transfection, 
then the cells were lysed for immunoprecipitation and immunoblot analysis.  C and 
D. CBP was cotransfected with either wt-EGFR or EGFR-K3R mutant into 
HEK293 cells.  The cell lysates were used for immunoprecipitation analysis. E.  
A431 cells were used for immunoprecipitation analysis.  
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Figure 9   CBP travels from the nucleus to the cytoplasm in response to EGF 
stimulation 
A.  A431 cells were serum-starved for 24h prior to the assay.  The cells were pre-treated 
with 5 M AG1478 for 6h before adding 25 ng/ml EGF and probed with an anti-CBP 
antibody for immunostaining.   Western blot was also performed to observe the effect of 
AG1478 on tyrosine phosphorylation of EGFR. B. The nucleus fraction and cytoplasm 
fraction of proteins from A431 cells were immunoblotted with indicated antibodies. 
(The figure 9B is adapted with permission from Elsevier Ltd) 
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Figure 10   Comparison of EGFR protein stability between wt-EGFR and EGFR-
K3R 
wt-EGFR and EGFR-K3R mutant were transfected into HEK293 cells and stable clones 
were generated and used for assay.  The cells were treated with 1 g/ml cycloheximide 
for indicated time and then collected for immunoblot analysis.  A549 cells were used as 
positive control.   
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Figure 11   Comparison of EGFR dimerization between wt-EGFR and EGFR-K3R 
wt-EGFR and EGFR-K3R were transfected into HEK293 cells.  After 48h expression, 
the cells were treated with BS3 cross-linker for 2h prior to collection.  The cell lysates 
were used for immunoblot analysis.   
 
 
 
 
 
 
 58
 
 
 
 
Figure 12   Comparison of protein localization between wt-EGFR and EGFR-K3R 
HEK293 stable clones for expressing either wt-EGFR or EGFR-K3R were seeded into 
chamber slide and cultured for 24h.  Then followed 24h serum starvation, the cells were 
treated with EGF for 30 min.  The cells were fixed and subject to immunofluorescence 
staining by using anti-EGFR and FITC-conjugated anti-IgG antibodies.  Confocal 
microscopy was employed to analyze the results (Done by Yi Du). 
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importantly, due to Y845 site at the center of the EGFR intrinsic activity pocket and 
phosphorylated by Src (232, 233), the mutation of K836 and K843 could possibly affect 
the interaction between EGFR and Src.  In addition, it has also been reported that Src 
can promote destruction of c-Cbl that may implicate oncogenic synergy between Src 
and EGFR (177).  To demonstrate the possible protein interaction affected by EGFR 
acetylation, we cotransfected Src with either wt-EGFR or EGFR-K3R mutant into 
HEK293 cells and performed immunoprecipitation analysis.  Our data demonstrated 
that the binding capacity of EGFR-K3R with Src was reduced more than 50% compared 
with wt-EGFR (Figure13A). The wt-EGFR transfectants treated by HDACi TSA 
significantly increased the interaction between Src and EGFR (Figure 13B). Together, 
these findings suggest that EGFR acetylation affects its interaction with Src.  Consistent 
with the literature, these data demonstrate that the change of EGFR modification could 
significantly affect the interaction between EGFR and its interacting proteins.   
 
3.1.8 EGFR acetylation enhances its tyrosine phosphorylation 
       To understand how EGFR acetylation affects its function, we compared 
phosphorylation of wt-EGFR with EGFR-K3R acetylation-deficient mutants.  Either 
wt-EGFR or EGFR-K3R mutant was transiently transfected into HEK293 cells.  The 
transfectants were grown in regular cell culture condition for 48h.  Then the cells were 
collected and subject to immunoblot analysis.  Meanwhile, wt-EGFR or EGFR-K3R 
was transfected into MCF7 breast carcinoma cells. The stable cell clones were selected 
and pooled for further analysis.   
       To compare EGFR activation between wt-EGFR and EGFR-K3R in normal growth 
environment, we grew both HEK293 and MCF7 transfectants for expression of either 
wt-EGFR or EGFR-K3R in normal DMEM with 10% FBS.  The cells were 
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immunoblotted for analyzing EGFR tyrosine phosphorylation.  Our result demonstrated 
that tyrosine phosphorylation of EGFR-K3R was significantly reduced compared with 
wt-EGFR (Figure 14). As the data will be shown later, TSA or SAHA increased EGFR 
phosphorylation. Considering that CBP increased EGFR phosphorylation and the 
knockdown of CBP significantly reduced EGFR phosphorylation (Figure 8), we 
concluded that EGFR acetylation affected its tyrosine phosphorylation. In addition, 
compared with wt-EGFR, EGFR-K3R significantly reduced its acetylation by CBP as 
showed in Figure 8C, further supporting that EGFR acetylation is associated with its 
tyrosine phosphorylation.   These data indicate an intrinsic correlation between 
phosphorylation and acetylation on EGFR.     
 
3.1.9 EGFR acetylation augments cell growth and DNA synthesis 
        To observe whether EGFR acetylation is indeed affected cellular function, we 
generated MCF7 stable clones and performed a series of cell-based function assays.  In 
vitro cell growth result showed that acetylation-deficient EGFR-K3R significantly lost 
its ability to stimulated cell growth compared with wt-EGFR (Figure 15), although the 
expression of EGFR was actually similar to each other.  Together, suggesting that 
acetylation status of EGFR but protein expression level affected cell growth.    
       Meanwhile, MCF7 stable cell clones were used for investigating whether EGFR 
acetylation affected DNA synthesis.   The results show that acetylation-deficient EGFR-
K3R mutant significantly reduced its ability to stimulate cell DNA synthesis in 
compared with wt-EGFR (Figure 16).  Together, these results suggest that EGFR 
acetylation could significantly affect its ability to regulate cell growth and DNA 
synthesis. 
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Figure 13   Protein interaction between EGFR and Src 
Either wt-EGFR or EGFR-K3R was cotransfected with Src into HEK293 cells. The 
transfectants were pre-treated by 20 M TSA for 5h.  A total of 500 g cell lysate was 
immunoprecipitated and immunoblotted with antibodies as indicated.  A. IP: EGFR.  B. 
IP: EGFR  C. input control. 
 
 
 62
 
 
 
 
 
 
Figure 14 Acetylation-deficient EGFR-K3R impairs phosphorylation of EGFR 
wt-EGFR or K3R mutant was transfected into different cells. The transfectants were 
culture for 48h in DMEM containing 10% FBS prior to collection.  A. HEK293 cells.  
A total of 20g of protein lysate was used for immunoblot analysis and probed with 
antibodies as indicated.  B. MCF7 stable cell clone.  Immunoprecipitation and 
immunoblot were performed by using antibodies as indicated. The quantitation of 
protein levels were normalized by densitometry and calculated as mean ± SD based on 
at least three independent data sets.   
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Figure 15  EGFR acetylation is associated with enhanced cell growth 
For function assays, MCF7 cell stable clones that express wt-EGFR or EGFR-K3R 
were established and used to perform the following function assays.  A.  1x104 
MCF7 parental cells or transfectants were plated into 6-well plates and subjected to 
cell number counting at different time points as  indicated.  The expression levels of 
wt-EGFR and EGFR-K3R were showed as well.  B. a total of 1,000 cells were 
seeded into 96-well culture plates.  MTT assay was performed.   
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Figure 16   EGFR acetylation is associated with increased cell DNA synthesis   
A total of 5x105  MCF7 parental cells or stable transfectants were seeded into 6-well 
culture plates and cultured to reach 90% confluence.  The cells then were serum-
starved for 36h and treated with BrdU for 18h prior to assay.  All data were 
calculated as mean ± SD and statistically analyzed by ANOWA and student’s t-Test.  
P<0.05 is considered as statistical significance.  
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Figure 17 EGFR acetylation is associated with increased cell anchorage 
independent growth 
A total of 5x104 MCF7 parental cells or transfectants were placed on the top soft 
agar gel in 6-well plates and cultured for 2-3 weeks.  The cell colonies were 
calculated as described in materials and methods.  All data were calculated as mean 
± SD and statistically analyzed by ANOWA and student’s t-Test.  P<0.05 is 
considered as statistical significance.  
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Figure 18  EGFR acetylation is associated with increased cell tumorigenesis in vivo 
MCF7 stable clone cells for expressing EGFR or EGFR-K3R were inoculated into 
mammary fat pads of nude mice.  The tumor size was measured by a standard method 
as stated in materials and methods section.  All data were calculated as mean ± SD and 
statistically analyzed by ANOWA and student’s t-Test.  P<0.05 is considered as 
statistical significance.  
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Figure 19 Proposed model for EGFR acetylation-induced cell growth and 
tumorigenesis 
Upon EGF stimulation, EGFR is acetylated by CBP, which resulted in the increase of 
Src interaction and EGFR phosphorylation.  These reactions may cause initiation of 
EGFR activation and subsequently activate EGFR downstream signal pathways.   
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3.1.10 EGFR acetylation is associated EGFR-induced tumorigenesis 
       To further study whether EGFR acetylation could impact cell tumorigenesis, we 
performed soft agar assay to observe cell anchorage independent growth by using 
MCF7 stable cell clones.   The result demonstrated that EGFR acetylation-deficient 
mutant lost its ability to augment EGFR-induced cell anchorage independent growth in 
the presence of either EGF or FBS as shown in Figure 17.   
 
3.1.11 EGFR acetylation is linked with EGFR-induced tumor burden 
       To investigate whether the impairment of EGFR acetylation could possible affect 
its oncogenic function in vivo, we generated MCF7 stable clones which could be used 
for in vivo animal tumor growth.  On the basis of observations above, the loss of 
function of acetylation-deficient EGFR-K3R in stimulating cell growth, DNA synthesis, 
and anchorage independent growth could consequently result in the reduction of its 
tumorigenic ability.  In this regard, we further investigated whether EGFR-K3R could 
support breast cancer MCF7 cell to grow tumor in vivo by using orthotopic animal 
model.  MCF7 stable clones for expression of either wt-EGFR or EGFR-K3R mutant 
were injected into mammary fat pads of nude mice and tumor sizes were measured.  As 
data showed in Figure 18, EGFR-K3R almost completely lost its ability to stimulate 
breast cancer MCF7 cells to grow tumor in nude mice.  Together, our in vitro and in 
vivo results supported that EGFR acetylation might play an essential role in regulating 
cell growth, DNA synthesis, and tumorigenesis.      
 
3.1.12 Proposed model 
       Based on our observations and knowledge from the current literature (4, 21, 22), we 
proposed a model for illustrating a possible mechanism by which EGFR acetylation 
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regulates cell growth and tumorigenesis.   As schematic diagram shown in Figure 19, in 
response to ligand stimulation, CBP is rapidly recruited to close proximity of EGFR in 
the cytoplasm and then acetylates EGFR.  The acetylated EGFR then enhances Src 
interaction with EGFR and together substantially augments EGFR phosphorylation.  
The augmented EGFR phosphorylation subsequently turns on EGFR-regulated 
downstream signal pathways and results in facilitated cell growth and tumorigenesis.      
 
3 .2 Clinical implications  
 
3.2.1 EGFR interacts with HDAC6 
       A431 cell lysate was immunoprecipitated by an anti-EGFR monoclonal antibody 
and immunoblotted by an anti-HDAC6 antibody.  The result showed that EGFR 
interacted with HDAC6.  In reciprocal immunoprecipitation, the similar result was 
observed (Figure 20).  Together, suggesting that EGFR and HDAC6 are physically 
associated with each other inside a cell that overexpresses EGFR.   
 
3.2.2 HDAC6 is overexpressed in various cancer cells 
       To examine whether HDAC6 expression is linked with cancers, we collected 
various types of cancer cell lines.  The cells were cultured with DMEM containing 10% 
FBS except HBE4 cells and then lyzed for immunoblot analysis.  The result showed 
that all cell lines expressed different levels of HDAC6 protein (Figure 21).  However, 
cancer cells expressed much higher levels of HDAC6 compared with non-cancerous 
cells.  For example, breast cancer cells MDA-MB-468 and lung cancer cells A549 
exhibited high expression levels of HDAC6.  In addition, it has been reported that 
HDAC6 is required for cell transformation and tumorigenesis (234).   Together, the data 
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Figure 20 The interaction between EGFR and HDAC6 is associated with 
EGFR-expressing cancer cells 
A total of 500 g A431 cell lysate was immunoprecipitated and immunoblotted with 
antibodies as indicated.  
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Figure 21   HDAC6 is highly expressed in various cancer cells 
The different cancer cell lines were lysed and the cell lysates were subject to 
immunoblot analysis using antibodies as indicated.   
 
 
 
 
 
 73
suggest that HDAC6 may be associated with cancers.  Although not all cancer cells 
with high level of HDAC6 express significant higher level of EGFR, the cancer cells 
with high EGFR expression generally exhibit high level of HDAC6,  implying that there 
is a correlation between HDAC6 and EGFR in the cell tumorigenic processes.   
 
3.2.3 EGFR-bearing cancer cells resist to HDAC inhibitors  
       A431 cells were treated with SAHA for 72h and MTT assay was performed to 
determine the survival rate of the treated cells.  Unexpectedly, we found the SAHA had 
minimal effect on growth and survival of A431 cells that express high level of EGFR 
(Figure 22A).  Immunoprecipitation and immunoblot analysis demonstrated that 
SAHA-treated A431 cells showed an increase in EGFR acetylation. By contrast, 
nicotinamide, a class III HDACi, had minimal effect on EGFR acetylation (Figure 
22B). 
      To examine whether SAHA induced abnormal cell growth in A431 cells is general 
phenomenon in subtype of EGFR-expressing cancers, we use another EGFR-expressing 
MDA-MD-468 breast cancer cells.  The cells were treated with SAHA for 72h and 
MTT assay was performed to determine the survival rate of the treated cells.  The 
similar result was observed (Figure 23A).  In contrast to this result, MDA-MB-453 
breast cancer cells with low level of EGFR were sensitive to SAHA treatment (Figures 
22A and 23A).  To investigate individual EGFR acetylation site upon SAHA treatment, 
we generated an antibody that was against lysine 843 acetylation on EGFR.   
Immunoblot analysis demonstrated that SAHA-treated MDA-MB-468 cells showed 
higher level of EGFR-K843 acetylation (Figure 23B).  Taken together, these result 
show that SAHA-enhanced EGFR acetylation may be associated with HDACi 
resistance in the treatment of EGFR-expressing cancers.   
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3.2.4 Knockdown of EGFR renders cancer cells sensitive to SAHA 
       To further understand the role of EGFR acetylation in SAHA-induced 
phosphorylation and resistance to SAHA treatment, we examined the effects of SAHA 
on the regulation of EGFR modification in high EGFR-expressing MDA-MB-468 and 
A431 cancer cells.  As data showed in Figure 22 and 23, SAHA induced EGFR 
acetylation and phosphorylation that resulted in cell resistance to SAHA treatment in 
A431 and MDA-MB-468 cells.  We also asked if the deletion of EGFR from these cells 
could re-sensitize the cells to respond to SAHA treatment.  The knockdown of EGFR 
by siRNA could make the cells to lose EGFR-dependent survival pathway, therefore, 
the cancer cells may become sensitive to SAHA treatment.  As expected, our result 
demonstrate that the knockdown of EGFR by siRNA rendered the cells sensitive to 
SAHA by using SAHA-resistant MDA-MB-468 cells (Figure 24).   Together, these data 
suggest that EGFR is indeed involved in SAHA resistance in MDA-MB-468 cells.    
 
3.2.5 Overexpression of EGFR  renders cancer cells resistant to SAHA  
       To further prove that EGFR will allow cells to regain resistance to SAHA, we 
overexpressed EGFR in MDA-MB-453 breast carcinoma cells to study whether the 
cells could become resistant to SAHA treatment.  MDA-MB-453 cells are originally 
very sensitive to SAHA treatment and express very low level of EGFR that is virtually 
undetectable.  After introducing EGFR into the cells, MDA-MB-453 cells became much 
more tolerant to SAHA treatment as showed in Figure 25, suggesting that EGFR was 
indeed contributed to SAHA resistance.    
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Figure 22  Acetylation of EGFR is associated with cancer cell resistance to HDACi 
A. A431 or MDA-MB-453 cells were treated with SAHA for 72h as doses indicated.  B. 
A431 cells were serum-starved then treated with 5 M SAHA or 4 mM Nicotinamide  
for 5h prior to collecting cells.  Then, immunoprecipitation and immunoblot were 
performed using antibodies as indicated.   
(The figure 22 is adapted with permission from Elsevier Ltd) 
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Figure 23  Acetylation of EGFR is associated with cancer cell resistance to HDACi 
A. MDA-MB-468 or MDA-MB-453 cells were treated with SAHA for 72h with 
different concentrations as indicated.  B. MDA-MB-468 cells were treated with 5 M 
SAHA for 24h.  Then, immunoblot was performed using antibodies as indicated.   
(The figure 23 is adapted with permission from Elsevier Ltd) 
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Figure 24   Knockdown of EGFR renders tumor cells sensitive to SAHA 
siRNA for knockdown of EGFR was transfected into MDA-MB-468 cells by 
electroporation. After 72h, the cells were treated with SAHA as indicated 
concentrations.  MTT assay was performed for measuring cell viability.  All data were 
calculated as mean ± SD and statistically analyzed by ANOWA and student’s t-Test.  
P<0.05 is considered as statistical significance 
(The figure 24 is adapted with permission from Elsevier Ltd) 
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Figure 25   Overexpression of EGFR renders tumor cells resistant to SAHA 
wt-EGFR for expression of EGFR was transfected into MDA-MB-453 cells. The stable 
cells were pooled and the cells were treated with SAHA as indicated concentrations.  
MTT assay was performed for measuring cell viability.  All data were calculated as 
mean ± SD and statistically analyzed by ANOWA and student’s t-Test.  P<0.05 is 
considered as statistical significance 
(The figure 25 is adapted with permission from Elsevier Ltd) 
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Figure 26  SAHA augments EGFR tyrosine phosphorylation in breast cancer cells 
MDA-MB-468 cells were treated with 2.5 M SAHA and/or 10 M erlotinib or 
gefitinib or lapatinib for 24h prior to collection.  The cell lysates were resolved on 8% 
SDS-PAGE and probed with antibodies as indicated. 
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3.2.6 SAHA-induced EGFR phosphorylation is linked with resistance 
       To understand the mechanism by which SAHA enhances cancer cell growth, we 
performed Western blot analysis using MDA-MB-468 breast cancer cells and found that 
SAHA indeed augmented EGFR phosphorylation, suggesting that SAHA-enhanced 
breast cell growth and survival were, at least in part, due to SAHA-enhanced EGFR 
phosphorylation that activated downstream survival pathway (Figure 26).  Our 
observation is also consistent with literature report (179).  These observations suggest 
that SAHA has an opposite effect due to the enhancement of EGFR phosphorylation 
that contributes to tumor cell survival and growth.  Given the fact that SAHA enhances 
phosphorylation of EGFR and could possibly augment tumor cell survival, we rationally 
considered that SAHA-enhanced EGFR phosphorylation is associated with protein 
acetylation, because SAHA as a HDAC inhibitor generally preserves protein 
acetylation.  As shown in Figures 22B and 23B, SAHA-treated A431 cells and MDA-
MB-468 cells all demonstrate elevated levels of EGFR acetylation.  Combined the data 
from Figures 22, 23, 24, 25, and 26, all of these evidence supported that EGFR 
acetylation-enhanced phosphorylation contributed to SAHA resistance in the cancer 
cells that overexpress EGFR.  These results suggested that SAHA-enhanced EGFR 
acetylation might be correlated with EGFR phosphorylation that contributed cancer 
cells to resist to SAHA treatment as a result.   
 
3.2.7 SAHA treatment and cell cycle change 
       To study cell cycle changes after the treatment of SAHA, MDA-MB-468 cells were 
treated by SAHA for 72h as doses indicated.  The results showed that SAHA induced 
cell cycle changes that mainly arrested in G2/M phase (Figure 27).  With increasing  
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Figure 27  Cell cycle change after SAHA treatment 
MDA-MB-468 cells were treated with SAHA for 72h and stained with PI.  The cells 
were analyzed by flow cytometry.    
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Figure 28   Combination of SAHA and EGFR inhibitors offsets cancer resistance 
to SAHA 
An MTT Assay was performed by plating 1x104 cells into 96-well plates. The cells were 
cultured for 72h in the presence of indicated TKI and/or SAHA.  All treatments were set 
up at least as triplets.  The data represent three independent experiments.  The cells 
were treated with 2.5 M SAHA in combination of erlotinib with indicated 
concentrations for 72h. A. A431 cells were treated with erlotinib with or without 
SAHA.  B. MDA-MB-468 cells were treated with erlotinib with or without SAHA.   All 
data were calculated as mean ± SD and statistically analyzed by ANOWA and student’s 
t-Test.  P<0.05 is considered as statistical significance.  
(The figure 28B is adapted with permission from Elsevier Ltd) 
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Figure 29 Combination of SAHA and EGFR inhibitors offsets cancer resistance to 
SAHA 
An MTT Assay was performed by plating 1x104 MDA-MB-468 cells into 96-well 
plates.  The cells were cultured for 72h in the presence of indicated TKI and/or SAHA.  
All treatments were set up at least as triplets. The data represent three independent 
experiments.  The cells were treated with 2.5 M SAHA in combination of either 
gefitinib or lapatinib with indicated concentrations for 72h. A. the cells were treated 
with gefitinib with or without SAHA.   B. the cells were treated with lapatinib with or 
without SAHA.  All data were calculated as mean ± SD and statistically analyzed by 
ANOWA and student’s t-Test.  P<0.05 is considered as statistical significance.  
(The figure 29 is adapted with permission from Elsevier Ltd) 
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Figure 30  Acetylation-deficient EGFR-K3R mutant abrogates SAHA-induced 
resistance 
Either wt-EGFR or EGFR-K3R was transfected into MDA-MB-453 cells. After 
expression and selection with corresponding antibiotics, MTT Assay was performed by 
plating 1x104 cells into 96-well plates and MDA-MB-453 cells were cultured for 72h in 
the presence or absence of indicated TKI and/or SAHA.  All treatments were set up at 
least as triplets.  The data represent three independent experiments.  For combination 
therapy, the cells were treated with 2.5 M SAHA in combination of 10 M erlotinib 
for 72h.  All data were calculated as mean ± SD and statistically analyzed by ANOWA 
and student’s t-Test.  P<0.05 is considered as statistical significance.  
(The figure 30 is adapted with permission from Elsevier Ltd) 
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Figure 31 Acetylation of EGFR may be related to HDACi-mediated sensitization to 
TKI 
A. T47D cells were treated with 5 M SAHA and/or 10 M erlotinib for 24h prior to 
collection. Immunoprecipitation was performed and the immunocomplexes were 
resolved on 8% SDS-PAGE and probed with antibodies as indicated.  B. T47D cells 
were treated with 5 M SAHA and/or 10M erlotinib for 72h prior to MTT assay. E+S: 
erlotinib and SAHA.  
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Figure 32 The signal pathways affected by combining SAHA and TKI in breast 
cancer cells 
MDA-MB-468 cells were treated with SAHA 2.5 M SAHA and/or 10 M erlotinib or 
gefitinib or lapatinib for 24h.  A. The cell lysates were resolved on 8% SDS-PAGE and 
probed with antibodies as indicated.  The quantitation of protein levels were normalized 
by densitometry and calculated as mean ± SD based on at least three independent data 
sets. B. The cell lysates from MDA-MB-468 cells were used for immunoprecipitation 
analysis.  Western blot was performed by using antibodies as indicated. 
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SAHA concentration, more cells were accumulated at G2/M phase.  All these data were 
consistent with literature reports.   
 
3.2.8 SAHA sensitizes tumor cells to respond to TKI in vitro 
       Since SAHA-enhanced EGFR acetylation induces its phosphorylation, we 
rationalize that EGFR signaling pathways may become dominant survival factors.  The 
blockade of EGFR may potentially benefit for targeting cancer cells that express EGFR 
based on oncogene addiction concept (235-237).   Therefore, we tested the combination 
of different TKI with SAHA.  A431 cells or MDA-MB-468 cells were treated with 
SAHA and/or erlotinib as doses indicated for 72h, and then cell viability was measured 
by MTT assay.  The results demonstrated that the combination of erlotinib and SAHA 
showed more effective killing in both EGFR-expressing cancer cells compared with 
erlotinib alone (Figure 28).   In addition, we tested different TKI to treat EGFR-
expressing cancer cells.  MDA-MB-468 cells were treated using SAHA with either 
gefitinib or lapatinib as doses indicated for 72h.  The similar results were observed as 
showed in Figure 29.  In addition, SAHA significantly lowered TKI dosage in the 
treatment of these EGFR-expressing cancer cells, especially in low dose ranges, SAHA 
demonstrated higher sensitization effects on cancer cells treated with TKI.  Taken  
together, our observations demonstrate that the combination of both HDAC and TKI 
could significantly benefit for cancer therapy in cancer cells that overexpress EGFR.    
       To further investigate whether EGFR acetylation is associated with SAHA-induced 
resistance, we transfected wt-EGFR or EGFR-K3R into MDA-MB-453 cells. After 48h 
expression, the cells were selected with blasticidin for two weeks.  The survival cells 
were then pooled for MTT assay.  The results showed that only wt-EGFR could render 
SAHA-sensitive MDA-MB-453 cells resistant to SAHA but not acetylation deficient 
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EGFR-K3R mutant (Figure 30).  Acetylation-deficient EGFR-K3R mutant did not have 
ability to help the cells to gain resistance to SAHA.  These data further suggested that 
acetylation of EGFR may link with SAHA resistance.  Combined the data that we 
observed previously, the augmented EGFR acetylation by SAHA consequently 
enhanced phosphorylation of EGFR, which may be responsible for SAHA resistance in 
EGFR-expressing cancer cells.   
       In addition to using EGFR overexpressing cancer cell lines, we also employed low 
EGFR-expressing breast cancer cell line T47D to investigate how the cells responded to 
SAHA.  T47D cells are insensitive to both TKI and SAHA treatment overall.  As shown 
in Figure 31, SAHA treatment increased EGFR acetylation as well as EGFR tyrosine 
phosphorylation (Figure 31A).  There was no effect of erlotinib on EGFR acetylation as 
shown in Figure 31A.  As a result, T47D cells became to respond to erlotinib treatment 
and showed about 40% killing effect in combination with SAHA and erlotinib (Figure 
31B).   This phenomenon may be also explained by oncogene addiction concept.       
       To understand the underlying molecular mechanism by which cancer cells were 
sensitized to respond to TKI in SAHA-treated cells that overexpress EGFR, MDA-MB-
468 cells were treated using SAHA with either erlotinib or gefitinib or lapatinib for time 
and doses indicated.  As expected, SAHA increased EGFR phosphorylation in MDA-
MB-468 cells (Figure 32A).  Consistent with previous observation, SAHA but not 
erlotinib increased EGFR acetylation in MDA-MB-468 cells (Figure 32B).  In addition, 
our observations suggest that Erk as a major downstream signal molecule was affected.  
In other words, MAPK signaling pathway was involved in SAHA-induced sensitization 
to TKI treatment in MDA-MB-468 breast cancer cells (Figure 32A).  In addition, p21 
protein expression was significantly increased upon the combination therapy.   These 
observations are consistent with reports in the literature (208, 209).   
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3.2.9 SAHA sensitizes cancer cells to respond to TKI in vivo 
       To further prove that combination therapy is indeed the best option for the 
treatment of cancers that overexpress EGFR, we performed in vivo animal study.  
MDA-MB-468 cells were injected into mammary fat pads of nude mice.  After tumor 
grew to designated sizes, the treatment was initiated.  A single drug or combination was 
administrated by oral daily.  The tumor sizes were measured twice a week.   The result 
showed that the combination of SAHA and erlotinib significantly reduced tumor burden 
in mice compared with either SAHA or erlotinib alone (Figure 33).  Either SAHA or 
TKI alone was less efficient to reduce tumor growth.  These data indicated that the 
combination of SAHA and TKI actually achieved significant inhibition of tumor growth 
in vivo, which might be attributed to SAHA-induced EGFR phosphorylation that 
triggered sensitization of cancer cells to TKI.   In addition, Western blot results 
demonstrated that SAHA alone could not inhibit Erk activity.  However, combined 
SAHA and TKI inhibited breast cancer MDA-MB-468 cell growth through 
downregulating Erk phosphorylation (Figure 32).  Together, suggesting that the 
sensitization effect might be attributed to SAHA-activated Erk that resulted in high 
response to TKI that mainly targeted EGFR/Erk signaling pathway in EGFR-expressing 
cancers.  All in all, our in vitro cell based data and animal study suggest that SAHA had 
potentials that could sensitize EGFR-expressing cancer cells to respond to TKI.  This 
sensitization action triggered by SAHA rendered TKI more effective to kill cancer cells 
that express EGFR.    
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Figure 33   The combination of SAHA and TKI increases therapeutic efficacy in 
the treatment of breast cancer in an orthotopic animal model 
MDA-MB-468 cells were injected into nude mice through mammary fat pad injection.  
After the tumors grew to designated size, the drugs were administrated by oral daily.  
The tumor volume was measured twice per week as indicated.  All data were 
calculated as mean ± SD and statistically analyzed by ANOWA and student’s t-Test.  
P<0.05 is considered as statistical significance.  
(The figure 33 is adapted with permission from Elsevier Ltd) 
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Discussion 
      Protein phosphorylation is the well understood field of protein posttranslational 
modifications (PTM), in which there are well-established models to study protein 
function in cellular regulation (65, 123, 145, 147, 148, 151, 189).  As we knew, protein 
phosphorylation is the most extensively studied filed .  Almost all aspects of cellular 
function and regulation are involved in protein phosphorylation.  For example, cell 
membrane protein regulation, signaling transduction, cell cycle regulation, DNA 
repairs, transcription and translation, protein stability and degradation, and etc (147, 
148, 189).  Accordingly, a variety of proteins need to be phosphorylated before 
functioning.  The switch and balance between protein phosphorylation and 
dephosphorylation control and dictate protein function and stability (123, 151).  The 
signaling transduction dictated by protein phosphorylation is well-established area that 
demonstrated that protein phosphorylation is a key and central even which is 
responsible for signaling cascades and protein function.  The loss of even a single 
protein phosphorylation could deviate entire signaling pathway and result in severe 
consequence including tumorigenesis and genetic deficiency (65, 148, 151).   From the 
cell surface to the nucleus, there is no exception that protein phosphorylation is essential 
for protein regulation and function.  The cell membrane proteins such as tyrosine kinase 
receptors need to be phosphorylated upon ligand stimulation.  Only after 
phosphorylation event occurs in membrane protein, membrane proteins could possibly 
form different structure and generate signaling cascades for cell cycle change and cell 
growth.  Even membrane protein turnover, phosphorylation is also an essential step for 
protein degradation and trafficking. The cytoplasmic proteins mainly play a role in 
transferring cellular signals into the nucleus.  Although some cytoplasmic proteins 
could be directly shuttled into the nucleus and interact with transcription factors to 
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regulate DNA replication, RNA transcription, and protein translation, however, the 
majority of cytoplasmic proteins still acts through phosphorylation cascades that pass 
signals to downstream molecules.  The MAPK, Akt, and Stat signal pathways are good 
examples to illustrate this scenario.  As far as transcription and nuclear proteins, they 
play a role in finally executing surface signals through the regulation of nuclear 
function that is in the center of the cells.       
       It has been shown that the majority of protein methylation and acetylation occurs in 
histone proteins that regulate transcription and translation.  Recently, more and more 
studies have found that many non-histone proteins are also methylated and acetylated 
including transcription factors and membrane proteins (167, 238).  For example, p53 
was reported to subject to methylation and acetylation modification that played an 
important role in regulating its protein stability and function (239-242).  Another report 
demonstrated that membrane interferon- receptor 2 was acetylated by CBP in response 
to interferon-ligand stimulation (228). These findings show that not only histone 
proteins but also most of cellular proteins are subjected to methylation and acetylation, 
which likely play a role in regulating cell behavior.  The recent discovery of various 
non-histone proteins as acetylation substrates (124, 144, 228, 243, 244) provides 
plausible evidence that protein acetylation may be critical for cellular processes and 
signal transduction (124, 228, 245).  The involvement of protein acetylation in cellular 
processes has widely spread in almost every aspect of the cells including membrane, 
organelles, cytoplasm, and the nucleus (124).  Therefore we raise a question: whether 
does protein acetylation have its own signaling pathway or just simply participate in 
protein phosphorylation-regulated signaling pathway?  This question remains elusive.  
The gain of insights about this question may help us to further understand how proteins 
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interact with one another and how protein codes will be marked and regulated.  To this 
end, understanding protein acetylation may be able to help us to develop more effective 
therapeutic drugs to treat related diseases.       
       In our study, we demonstrated that EGFR could be acetylated by CBP with 
knockdown and overexpression approaches. Three acetylation sites in EGFR were 
identified.  We also observed that EGF rapidly triggered CBP to shuttle out the nucleus 
and approach to EGFR in close proximity of cell membrane.  This observation was 
similar to previously reported that INF- triggered CBP moved from the nucleus into 
the cytoplasm and then acetylated INF-R2 (228).  Although CBP is mainly located in 
the nucleus, however, there is small percentage of CBP located into the cytoplasm, 
which may explain basal levels of EGFR acetylation prior to EGF stimulation.  In fact, 
the EGFR overexpressing cells exhibit relative high level of EGFR acetylation without 
ligand stimulation that may be attributed to the remains of CBP in the cytoplasm.  
However, it is unclear what role EGFR acetylation plays in this stage.  One possibility 
is that acetylation of EGFR prior to ligand stimulation may be responsible for initiation 
of EGFR phosphorylation and dimerization.  Since lysine 836 and 843 are physically 
close to Y845,   which is one of reported Src phosphorylation sites (233).  We speculate 
that the triad formed by K836, 843 and Y845 may be an important structure for 
recruiting Src to initiate EGFR activity.  Several reports about EGFR structure and 
function demonstrated that EGFR membrane structure but not ligand-induced tyrosine 
phosphorylation was critical and essential for initiating EGFR dimerization and 
activation (16, 226, 246). The mutation of these critical structure sites could abrogate 
EGFR activation.  These reports seem consistent with our observations.   As far as the 
role of Src in EGFR activation and function, there are a few reports in which 
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demonstrated different observations and results.  One report showed that Src was 
required for Y845 phosphorylation  and autophosphorylation at Y1068 on EGFR.  Src 
inhibitor reduced Y845 phosphorylation and Y1068 autophosphorylation (188).  These 
observations suggested that Src might be required for EGFR transphosphorylation, 
autophosphorylation, activity, and function. However, there is another seemingly 
controversial report in which showed that Src was not required for EGFR kinase 
activity (187).   In that report, the authors demonstrated that although Src-
phosphorylated Y845 on EGFR was required for regulating cell growth, DAN 
synthesis, and tumorigenesis, Y845 phosphorylation status had nothing to do with 
EGFR kinase activity.  In comparison of wt-EGFR and EGFR-Y845F mutant, the 
kinase activity was similar to each other in an in vitro kinase assay.  Interestingly, there 
is a report in which even showed that the position and structural proximity of the key 
amino acids in enzymatic pocket but not tyrosine phosphorylation on EGFR was 
responsible for the initiation of EGFR dimerization and activation (16).   It seems that 
there was no a common ground with respect to how to explain the initiation of EGFR 
activity.  Therefore, the questions are raised as follows: 1. what event is the first step 
and critical for EGFR activation, dimerization or phosphorylation?  2. As Src is the only 
currently known kinase that tyrosine phosphorylates EGFR, is there a role of Src in 
activating EGFR?  3. What kind of relationship is among Src-associated EGFR 
transphosphorylation, autophosphorylation, and EGFR kinase activity?  There are no 
convincing answers yet based on the literature that we can find about EGFR study.  
However, the further understanding of these issues may be important for decoding 
EGFR acting mechanisms and targeting EGFR-associated diseases including cancers.       
       Broadly speaking, PTM of protein usually affect protein stability, protein 
trafficking, and protein-protein interaction.  In our study, in comparison of wt-EGFR 
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and acetylation-deficient EGFR-K3R mutant, the protein stability and trafficking were 
not affected.  The difference that we observed was protein-protein interaction.  Several 
critical proteins such as Src showed weak interaction with EGFR-K3R mutant.  An 
average of 50% reduction of Src protein binding was observed in EGFR-K3R mutant 
compared with wt-EGFR.  Considering the loss of tyrosine phosphorylation in EGFR-
K3R, there may have some intrinsic links between acetylation and phosphorylation of 
EGFR.  The cellular study results suggest that EGFR acetylation affected its 
phosphorylation and protein interaction, which proved by EGFR-K3R mutant and 
HDACi treatment.  These observations may be further evidence that EGFR acetylation 
was important for the initiation of EGFR activation through regulating its 
phosphorylation.  In addition, the treatment of EGFR-expressing cells with TKI did not 
change EGFR acetylation level, which may suggest that EGFR acetylation occurs 
before its phosphorylation.  However, further study is needed to demonstrate whether 
EGFR acetylation is essential for its phosphorylation. The understanding of dependency 
or causal relationship between EGFR acetylation and phosphorylation could be very 
useful for deciphering EGFR function and designing therapeutic strategies to target 
EGFR-associated cancers.   
       EGFR acetylation also played an important role in regulating EGFR/Src protein 
interaction.  Based on our observations, we speculate that the acetylated EGFR may be 
required for the recruitment of Src.  As a result of Src binding to EGFR, the activation 
of EGFR will be initiated.  In other words, what EGFR acetylation enhances Src 
recruitment may be essential for the initial activation of EGFR.  Our observation of 
which acetylation deficient EGFR-K3R lost EGFR kinase activity further supports this 
postulation (data not shown).  In addition, considering that CBP-catalyzed EGFR 
acetylation consequently augmented EGFR phosphorylation, we consider that these 
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observations support the notion of which EGFR acetylation may be required for the 
initiation of EGFR activity.   
       HDACi have become a hot spot in therapeutic application recently, especially in 
cancer treatment. With HDAC class I and II inhibitor SAHA being approved for 
treating lymphoma by FDA, more HDACi are under developing and/or undergoing 
clinical trial (167, 169, 174).  However, our observations also raise a safety issue about 
application of HDACi in EGFR-expressing diseases. On the basis of enhanced EGFR 
phosphorylation by SAHA-induced EGFR acetylation, it may be general phenomenon 
that HDACi could augment EGFR phosphorylation and then subsequently trigger 
EGFR activation and oncogenic function in the cancer cells expressing EGFR. The 
consequence may be severe.  To avoid this unwanted problem, our results imply that 
TKI should be included in the intervention.  Interestingly, HDACi can actually sensitize 
the cells to respond to TKI, which can be explained by oncogene addiction concept.  
Our in vitro and in vivo data all support that SAHA has sensitization effect on EGFR-
expressing cancer cells.  We considered what SAHA sensitized EGFR-expressing 
cancer cells to respond to TKI was a case that could be explained by oncogene 
addiction concept.  According to this theory, in response to environment or therapeutic 
intervention, the affected cancer cells would adapt to survive by depending on a single 
intensified signal pathway, namely acquired dependency.  Due to the increase of 
dependency to this surrogate survival pathway, the affected cells became more 
susceptible to the inhibitors that target this more demanding pathway.  Therefore the 
sensitization effect can be achieved by the addition of inhibitors to block such a 
pathway.  The expression of wt-EGFR but not acetylation-deficient EGFR resulted in 
the gain of resistance to SAHA in SAHA-sensitive cells, suggested that EGFR 
acetylation could be an important mechanism that caused cell resistance to SAHA.  
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       The study on EGFR acetylation unveiled insights about mechanism(s) of possible 
acetylation-regulated phosphorylation on the cell surface tyrosine kinase receptors. 
Meanwhile, acetylation-augmented EGFR phosphorylation “has an important clinical 
implication, predicting that EGFR-expressing cancer cells may be resistant to a single 
HDAC inhibitor treatment” (223).  One of the possible mechanisms is due to enhanced 
EGFR/Src interaction and/or acetylation-enhanced EGFR tyrosine phosphorylation.   A 
therapeutic regimen of combined HDACi with TKI could take advantage of HDACi-
induced EGFR phosphorylation, which makes EGFR more accessible and vulnerable to 
TKI according to the oncogene addiction concept.  The underlying molecular 
mechanism may mainly act through Erk signal pathway in various cancer cells as 
reported in the literature (247-252).  Although EGFR-regulated Akt and Stat signaling 
pathways were also involved in various cancer cells in the treatment of TKI, however, 
Erk pathway has always been involved in most cases.  In addition, HDACi-enhanced 
phosphorylation of Erk was also reported in the literature recently (249).  Consistent 
with this report, we also demonstrated that SAHA induced Erk phosphorylation in 
EGFR-expressing breast cancer cells.  The HDACi-activated Erk pathway may provide 
a surrogate survival pathway for the cancer cells treated by HDACi alone to survive.  
Our observation suggest what SAHA sensitized cancer cells to respond to TKI was also 
mainly through down-regulation of Erk signaling.  In the cells treated with SAHA, Erk 
phosphorylation was elevated.  However, the elevated Erk was effectively inhibited by 
the addition of TKI, since TKI mainly target Erk signaling pathway (21, 253-259).   
       Currently, using deacetylase inhibitors as therapeutic drugs is an extensively 
explored field (126, 171, 174, 260, 261).  There are more than 160 worldwide multi-
center clinical trials (this number is increasing steadily) listed on the NCI website.  
Among those trials, more than 50% are involved in assessing SAHA for the treatment 
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of various cancers.  The combination of SAHA and TKI is also included in those multi-
center clinical trials.  Since SAHA seems to be a very promising anti-cancer agent with 
the property of excellent bioavailability, low toxicity and few side effects. In addition, 
SAHA can be orally administrated that makes SAHA practically more attractive.  
However, there is safety issues emerged from EGFR-expressing cancers.  Our 
observations by using SAHA in vitro and in vivo not only raised a safety issue about 
SAHA, but also we provided a possible explanation about the underlying mechanism.    
Our study provided an insight into direct involvement of EGFR acetylation in response 
to HDACi treatment to human cancers, which suggested that using these inhibitors 
alone could have adverse effects on EGFR-expressing cancers.  In this scenario, the 
combination of HDACi and TKI may be a better option to prevent potential risks from 
patient treatment provided that HDACi regimen becomes necessary.  Our in vivo animal 
study also supported that the combination of SAHA and TKI actually achieved better 
therapeutic outcome compared with an individual agent alone. These observations are 
consistent with reports in the literature (222).  Given the fact of the potent 
pharmacological effect and increasing popularity of HDACi such as SAHA for cancer 
treatment, our observations suggested when using HDACi alone to treat EGFR-addicted 
cancers, caution should be taken due to the potential HDACi-enhanced EGFR 
oncogenic function and combination therapy may need to be considered accordingly. 
 
 Summary 
       EGFR, as an essential growth and survival factor, plays an important role in cancers 
of the lung, breast, brain, ovary, skin, and head and neck.  The modification patterns of 
EGFR are critical for its function and the understanding of these EGFR modifications 
could help us to design the optimal therapeutic strategies for targeting various EGFR-
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associated cancers and/or non-cancerous diseases.  We observed that EGFR acetylation 
as a novel protein posttranslational modification might play a very important role in the 
early regulation of EGFR signaling pathways.  We identified that CBP was an acetylase 
responsible for EGFR acetylation.  Our data suggest that EGFR acetylation mainly 
affects its protein interaction. EGFR dimerization, protein stability, trafficking, and 
localization were not significantly different between wt-EGFR and acetylation-deficient 
EGFR-K3R mutant. Our study demonstrated that EGFR acetylation upregulated its 
phosphorylation and subsequently augmented cell growth and tumorigenesis.   
       We also expanded our study into translational field in order to understand the 
indication of EGFR acetylation in the clinical settings.  As we demonstrated as before, 
what HDACi including SAHA treated EGFR-expressing cancer cells could 
subsequently gain resistance to HDACi due to the augmented EGFR phosphorylation.  
The combination of HDACi and TKI can effectively inhibited cell growth and 
tumorigenesis, due to the nature of that TKI could block the acetylation-augmented 
phosphorylation and activation of EGFR, while synergistically enhanced SHAH-
induced p21 protein expression.  In addition, we also demonstrated that MAPK 
signaling pathway was downregulated in this combination approach.  Together these 
actions resulted in cancer cell death. Our study provides an experimental rationale that 
supports combination therapy of HDACi and TKI in the treatment of a subtype of 
cancers that overexpress EGFR.     
 
Future Directions 
      There are still several unaddressed questions that need to be addressed regarding 
EGFR acetylation.  First of all, our study provided evidence that elucidated EGFR 
acetylation was an early event prior to its phosphorylation.  It has been reported that 
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more than 80 proteins interact with EGFR prior to activation, suggest that EGFR is 
actually involved in dynamic protein-protein interactions (208).  It is of interest to 
understand how the initiation of EGFR activation occurs and how the protein 
interactions are regulated.    
       Second, acetylation-enhanced EGFR phosphorylation plays an important role in 
regulating cell growth and tumorigenesis.  Besides these function, is there addition 
function with respect to EGFR acetylation?  It is also of interest to understand how 
these modifications reconcile one another and together regulate EGFR function.    
       Third, it is still unclear how EGFR acetylation, autophosphorylation, and 
transphosphorylation by Src interact in EGFR activation and function.   Little is known 
about the relationship of the kinase activity of EGFR with these modifications.  
However, the understanding of these questions can be very important for studying 
EGFR function and developing therapeutic strategies for targeting EGFR-expressing 
cancers.  
       Lastly, it is also very important to understand how EGFR acetylation is regulated.  
Is EGFR acetylation inducible?  The insights about the regulation of EGFR acetylation 
will be helpful for clinical applications.  For example, to guide physicians to design 
HDACi regimens, while to avoid adverse effects in the treatment of EGFR-expressing 
cancers.   
       In summary, the aberrant expression of EGFR is involved in various cancers. 
According to the literature, what the mutations and modifications of EGFR affect its 
function mainly acts through the regulation of EGFR phosphorylation and downstream 
signal pathways.  Gaining knowledge of EGFR modifications could help us to better 
understand how cancer resistance occurs and develop alternative strategies to treat 
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theses cancers.  Therefore, the elucidation of EGFR modifications could potentially 
benefit for the treatment of EGFR-related cancers.   
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